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Chapter 1 
 
Introduction 
 
1. Curcumin  
1.1. Introduction to curcumin 
 The chemical structure of curcumin is 
shown in Figure 1.1. Curcumin is a major 
secondary metabolite of the perennial Asian 
plant turmeric (Curcuma longa L). Curcumin 
was identified as the active principle of turmeric in 1815, and its structure 
determined after crystallization in 1870 (Ravindran, Prasad, and Aggarwal 2009). 
Turmeric is only one representative of more than 80 curcuma species of the 
ginger family, Zingiberaceae (Leong-Skornicková et al. 2007; Sasikumar 2005). 
Turmeric is widely cultivated in many Asian countries particularly in India where it 
is grown mostly for dietary use, and is a major component of the spice curry. 
Additionally, turmeric is recognized for its medicinal properties, and has been 
used for centuries in the treatment of a variety of ailments including eczema, 
arthritis, ulcers, asthma, anemia and many others (Goel, Kunnumakkara, and 
Aggarwal 2008). Resulting from extensive studies over the last few decades, 
curcumin has emerged as a promising anti-cancer agent and has been shown to 
target multiple and diverse signaling pathways involved in disease causation and 
progression (Aggarwal & Harikumar 2009; Singh & Khar 2006). The 
FIGURE 1.1 Structure of curcumin. 
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attractiveness of curcumin as a therapeutic agent is enhanced by its safety, 
affordability, and history of long-term use (Chandran and Goel 2012; Belcaro et 
al. 2010). 
 
1.2 Curcuminoids 
 Curcuminoids refer to the mixture of curcumin and its two structurally 
related isomers, demethoxycurcumin and bisdemethoxycurcumin, shown in 
Figure 1.2. (Tonnesen and Karlsen 1985). Demethoxycurcumin and 
bisdemethoxycurcumin lack one or both of the methoxy groups attached to the 
phenolic rings in curcumin, respectively. Together, curcuminoids constitute about 
4–6% of the mass of dried turmeric rhizome. Curcumin is by far the most 
abundant, accounting for more than 80% of the total curcuminoids (Jacob et al. 
2007). Commercial preparations of curcumin contain a mixture of about 80% 
curcumin, 15% demethoxycurcumin and 5% bisdemethoxycurcumin (Goel, 
Kunnumakkara, and Aggarwal 2008). 
 
 
 
 
1.3 Chemical and physical properties of curcumin  
 The IUPAC name of curcumin, also referred to as diferuloylmethane, is 
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione. It has a 
FIGURE 1.2 Structure of the minor curcuminoids.
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molecular formula of C21H20O6, corresponding to a molecular weight of 368.37. 
Curcumin is a yellow-orange crystalline powder with maximum absorbance at 
430 nm and melting point of 183 °C (Goel, Kunnumakkara, and Aggarwal 2008). 
Curcumin exhibits hydrophobic and (slight) hydrophilic properties owing to its 
aliphatic heptadienone linker and polar -dicarbonyl and phenolic groups, 
respectively (Balasubramanian 2006; Grynkiewicz and Ślifirski 2012). Curcumin 
is sparingly soluble in water, but shows greater solubility in some organic 
solvents such as acetone, ethyl acetate, acetonitrile and ethanol. Its reported 
partition coefficient (Log P) ranges from 2.5 to 3.3 (Grynkiewicz and Ślifirski 
2012). Curcumin is a bis--unsaturated -
diketone, and exists in equilibrium with its 
enol tautomer (Chignell et al. 1994). Studies 
involving 1H, 13C NMR, and infrared 
spectroscopy have shown that the enolate 
form predominates in alkaline solution (Sun 
et al. 2010; Jacob et al. 2007). Further, the 
enolate form is energetically favored since 
curcumin then exists as a completely 
conjugated and planar structure (Sun et al. 
2002; Sun et al. 2010). In the enolate 
conformation in alkaline conditions, the 
phenolic hydroxyl is the major site of curcumin reactivity; curcumin donates a 
proton and an electron from either of its phenolic hydroxyls via the 'Sequential 
FIGURE 1.3  Enol (pH 8) versus 
bis-keto (pH 3) tautomers of 
curcumin, and  their different 
site of  H-donation. 
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Proton Loss Electron Transfer' (SPLET) mechanism, resulting in a phenoxyl 
radical. (Litwinienko and Ingold 2004). The donation of a phenolic H underlies 
curcumin's antioxidant activity and its instability at alkaline pH (Strimpakos and 
Sharma 2008; Griesser et al. 2011; Wang et al. 1997). In contrast, under acidic 
conditions, the bis-keto form of curcumin predominates and it becomes a potent 
H donor from the weak central C–H bond (Sun et al. 2002; Litwinienko and Ingold 
2004; Pandya et al. 2012; Jacob et al. 2007) (Figure 1.3). Up to eight different 
conformational isomers of the enolic curcumin have been proposed from 
crystallization studies, with three crystalline forms exhibiting varying degrees of 
solubility identified depending on the type of solvents used for extraction and 
purification. All three crystalline forms exist as the -keto–enol tautomer but differ 
in their hydrogen bonding, molecular packing, and the relative orientation of the 
keto–enol groups in neighboring molecules. Form 1, the type typically seen in 
commercial preparations of curcumin, has a slightly twisted conformation. Forms 
2 and 3 show a linear, planar conformation and have a slight increase in solubility 
compared to form 1 (Grynkiewicz and Ślifirski 2012; Sanphui et al. 2011).  
 
1.4 Therapeutic potential of curcumin 
 Like many other natural products with 'roots' in ethno-medicine, curcumin 
is now the subject of extensive research and is among the most studied plant 
derived medicinal chemicals (Grynkiewicz and Ślifirski 2012).  Curcumin is widely 
recognized for its potent anti-inflammatory effects, and is associated with 
reduction in neutrophil and macrophage infiltration, inhibition of pro-inflammatory 
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chemokines, and suppression of NF-κB, COX-2, iNOS, IL-8 and other pro-
inflammatory targets in vitro and in animal models (Wilken et al. 2011; Weisberg, 
Leibel, and Tortoriello 2008; Weber et al. 2006). Inflammation is central to the 
progression of many chronic diseases such as cancer, cardiovascular disease, 
diabetes, neurodegenerative disease, and arthritis, and curcumin is being 
investigated in the treatment and prevention of these diseases (Hong et al. 2010; 
Chandran and Goel 2012; Chanpoo et al. 2010; Weisberg, Leibel, and Tortoriello 
2008; Ono et al. 2004; Quitschke, Steinhauff, and Rooney 2013). Suppression of 
prostaglandin (PGs) synthesis through the inhibition of COX-2, for example, is 
associated with decreasing inflammation and cancer cell proliferation. (Suzuki et 
al. 2009; Valacchi et al. 2004; Marcu et al. 2006; Weisberg, Leibel, and 
Tortoriello 2008; Chen et al. 2007).  
 Epidemiological studies have linked the high consumption of 
curcumin/turmeric in India (up to 1.5 g per person daily) to the lower overall 
incidence of colorectal, pancreatic, lung, breast, and prostate cancers when 
compared to Western countries where little curcumin is consumed (Aggarwal and 
Harikumar 2009). Furthermore, second generation migrants from India show 
higher cancer prevalence than their first generation counterpart, further 
solidifying an environmental (or dietary) basis for the discrepancy in cancer 
prevalence (Wilken et al. 2011; Sinha et al. 2003).  
 Pre-clinical studies of curcumin in rodent models show efficacy against 
colonic, stomach, liver, breast, pancreatic, brain and lung cancers (Johnson & 
Mukhtar 2007; Singh & Khar 2006; Singh et al. 2013; Ranjan et al. 2013; Perry et 
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al. 2010; Su et al. 2010). Curcumin exhibits chemopreventive effects against 
cancer caused from germline mutation in the APC gene in C57BL/6J-Min/+ mice 
that show spontaneous intestinal adenomas, or cancer caused from the 
carcinogens DMBA, benzo[a]pyrene, and azoxymethane that induce lymphomas, 
stomach and colon carcinogenesis, respectively (Mahmoud et al. 2000; Huang, 
Newmark, and Frenkel 1997; Huang et al. 1998). The chemopreventive effects of 
curcumin in mouse models support its role in the low incidence of cancers in 
regions where turmeric forms a major part of the diet. Curcumin is also able to 
reduce tumors once they are formed in animals. Studies conducted in tumor 
xenograft mice shows that curcumin can reduce or cure brain tumors, pancreatic 
tumors, lymphomas, and others (Perry et al. 2010; Aoki et al. 2007; Ranjan et al. 
2013; Li et al. 2009). 
  In mouse models of diabetes, curcumin treatment results in 
improvements in obesity, blood glucose levels, as well as glucose and insulin 
tolerance. Curcumin was shown to 
significantly decrease body weight 
and fat content even with increasing 
caloric intake, and protects 
pancreatic islets against disease 
related damage. The improvements 
in glycemic status were coupled with 
decreased NF-κB signaling, reduced 
macrophage infiltration into adipose 
FIGURE 1.4 Number of curcumin clinical
trials registered at www.clinicaltrials.gov.
every other year since 2001. 
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tissue, and higher circulating adiponectin levels (Weisberg, Leibel, and Tortoriello 
2008; Chanpoo et al. 2010). Curcumin also shows efficacy in models of 
depression, Alzheimer's disease, and cardiovascular disease (Olszanecki et al. 
2005; Zhao et al. 2013; Quitschke, Steinhauff, and Rooney 2013).  
 Extensive preclinical data showing efficacy for curcumin led to studies in 
human diseases. There is a growing number of clinical studies involving 
curcumin, reaching 92 as of March 2014, up from 2 studies in 2001 (Figure 1.4). 
A study by Hishikawa et al. investigated turmeric in three Alzheimer's disease 
(AD) patients with severe cognitive, behavioral and psychological decline. The 
patients were given 100 mg/day curcumin for 12 weeks. The authors reported 
significant improvement in behavioral symptoms with no adverse effects seen 
even after 1 y of taking the drug (Hishikawa et al. 2012). The mechanism of 
action for curcumin in AD has not been elucidated. Current strategies for treating 
the disease use inhibitors of glutamate and acetylcholinesterase (AChE). 
Curcumin has been shown to protect against glutamate excitotoxicity (Wang et 
al., 2008) and inhibit AChE in in vitro assays. Furthermore, curcumin shows 
memory-enhancing effects in rodent models (Ahmed & Gilani, 2009), exhibits 
anti-amyloid activity (Ono et al., 2004) and can lessen inflammation in the brain 
(Akiyama, 2000) as possible mechanisms of its effects on AD. 
 Studies in arthritis patients report improvements in disease activity and 
improved overall quality of life in patients taking 200 mg (open label) or 500 mg 
meriva curcumin per day (Belcaro et al. 2010; Chandran and Goel 2012). 
Additionally, curcumin shows efficacy in patients with ulcerative colitis, diabetes, 
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colorectal cancer, and other diseases (Hishikawa et al. 2012; Hanai et al. 2006; 
Chuengsamarn et al. 2014; He et al. 2011).  
 
1.5 Curcumin as an antioxidant 
The effects of curcumin were first attributed to its antioxidant properties 
(Jurrmann, Brigelius-Flohé, and Böl 2005). Curcumin has a uniquely conjugated 
phenolic structure making it a particularly good radical trapping antioxidant (Al-
Amiery et al. 2013). Curcumin can reduce oxidative damage in cells by 
preventing lipid peroxidation, increasing reduced glutathione by inducing its 
biosynthesis, and scavenging small free radical species like HO• and ROO• 
(Barzegar and Moosavi-Movahedi 2011; Jat et al. 2013). There was some 
contention in the literature over the relative importance of the phenolic hydroxyl 
versus the central methylenic hydrogen in mediating the antioxidant effect of 
curcumin. Jovanovic and his collaborators concluded that curcumin donates its 
H-atom from the central methylenic group in aqueous acidic buffer and in 
acetonitrile solutions (Jovanovic et al. 2001). It was later proposed that under 
physiological conditions, curcumin is a typical phenolic antioxidant and donates 
an H-atom from one of its phenolic hydroxyls (Barclay et al. 2000; Priyadarsini et 
al. 2003; Barzegar and Moosavi-Movahedi 2011). The meta-methoxy groups 
were suggested to further increase its antioxidant activity (Sun et al. 2002). 
 During anti-oxidant reactions, the donation of an H-atom and electron to 
an oxidized species creates a second radical (albeit a more stable one) in the 
antioxidant molecule (a phenoxyl radical in the case of curcumin). This 
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secondary radical must then be terminated by another radical species. An 
important clue to understanding the anti-oxidant mechanism of a compound is 
the structural elucidation of the terminated antioxidant product (Masuda et al. 
1999). Masuda et al conducted model studies of curcumin oxidation using 2,2‘-
azobis(isobutyronitrile) to produce the curcumin radical in acetonitrile. The 
authors reported isolating chain cleavage products vanillin and ferulic acid, as 
well as dimers of curcumin. A mechanism was proposed in which curcumin is 
first converted to the phenolic radical that moves to a carbon centered position 
along the heptadienone chain resulting in the formation of a quinone methide. 
The dimers, they further proposed, were formed from coupling of two different 
carbon-centered radical species, and vanillin and ferulic acid formed from radical 
chain cleavage. Studies in our lab show that in aqueous solution, the terminal 
product(s) involves the stable incorporation of oxygen into the molecule to form a 
bicyclopentadione, with no products from inter-molecular curcumin reactions 
observed (Griesser et al. 2011; Gordon & Schneider 2012). The reaction of 
curcumin to generate the bicyclopentadione is the main focus of the work 
presented in this dissertation. 
 
1.6 Intermolecular interactions of curcumin. 
 In addition to its anti-inflammatory and anti-oxidant effects, curcumin 
exhibits antiviral, antibacterial, antifungal, antineoplastic, and antiangiogenic 
bioactivities (Barclay et al. 2000; Nafisi et al. 2009; Perry et al. 2010; F. Chen 
and Shi 2002). Curcumin modulates more than 100 cellular targets in in vitro 
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studies using cell-based systems (Anand et al. 2008). Curcumin has been shown 
to affect transcription factors (AP-1, PPAR-γ), cytokines (IL-1, IL-2, IL-5, IL-12), 
enzymes (MMP-1, GST, 5-LOX), growth factors (EGF, VEGF, TGF1), kinases 
(PKA, PKB, JNK, MAPK) and survival pathways (p53, Bcl-2) in many cell types 
(Johnson and Mukhtar 2007; Jurrmann, Brigelius-Flohe, and Bol 2005; Valacchi 
et al. 2004; Awasthi et al. 2000; S. Singh and Khar 2006; Ravindran, Prasad, and 
Aggarwal 2009). 
Affecting this many targets is a remarkable feat for any single molecule. 
The chemical mechanisms whereby curcumin is able to achieve this is one 
conundrum associated with its biological effects. The chemical properties of the 
curcumin molecule provide many inferences into the nature of its interactions 
with protein targets and may explain its interaction with some of its targets. The 
following features of curcumin are implicated in mediating its intermolecular 
interactions: lipophilicity; Michael reaction acceptor capacity; H-bond donating 
capacity of the β-diketo and phenolic hydroxyl moieties; and its rotamerization 
capacity (Figure 1.5).  
 
HO
H3CO
O-H
OCH3
O O
C-C bond rotation sites Michael acceptor site
H-atom donation
M2+
complex with divalent cation
High Partition Coefficient  
FIGURE 1.5 Chemical properties of curcumin  
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The high lipophilicity of curcumin has been attributed to the aliphatic 
heptadienone linker connecting the more polar methoxyphenol rings. Lipophilicity 
allows for non-covalent interactions with hydrophobic residues in proteins (Liu et 
al. 2008). Molecular docking studies show interactions between curcumin and 
alanine and tyrosine residues in human immunoglobulin G (Liu et al. 2008). 
Docking studies of curcumin in COX-1 active site show that the aliphatic chain 
region of curcumin is surrounded by hydrophobic amino acids, including leucine, 
alanine, and valine (Heger et al. 2014a; Selvam et al. 2005). Curcumin also binds 
in the minor and major groove of DNA at AT-rich regions (Bera et al. 2008; Nafisi 
et al. 2009). The strong hydrophobic binding of curcumin to its target proteins 
stabilizes further covalent interactions between the two molecules (Leung and 
Kee 2009). 
The Michael acceptor capacity of curcumin allows for covalent 
interactions with nucleophilic residues in proteins (thiolates and amines) at its 
α,β-unsaturated carbonyl positions (Figure 1.5). A common Michael reaction 
involving curcumin is with glutathione (GSH). The GSH tripeptide is composed of 
-glutamate-cysteine-glycine and is known for its nucleophilic reaction with α,β-
unsaturated carbonyl compounds (Ketterer 1988; Awasthi et al. 2000). 
Incubation of curcumin with GSH led to a concentration and time-dependent 
decrease in the curcumin chromophore at 430 nm, due to the disruption in the 
conjugated system resulting from covalent adduction (Awasthi et al. 2000). 
Curcumin-GSH adducts have been confirmed by HPLC, LC-MS and NMR 
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studies (ON Gordon, unpublished). One study suggesting covalent adduction of 
curcumin with p300 in cells uses the lack of reactivity of the protein with 
tetrahydrocurcumin (which lacks the α,β-unsaturated carbonyl) as evidence of 
Micheal reaction with curcumin (Marcu et al. 2006). Covalent interaction of 
curcumin with many of its target proteins has not been demonstrated. 
 Lastly, curcumin undergoes rotamerization about multiple a C–C bonds. 
This conformational flexibility maximizes the number of interactions between 
curcumin and its targets, as evident from the docking studies in which curcumin 
tends to adopt different configurations for each molecular target (Heger et al. 
2014a). Curcumin retains its planar structure when interacting with B-form DNA 
minor grooves, and becomes nonplanar when bound to amyloid protein and PKC 
(Heger et al. 2014a; Koonammackal, Nellipparambil, and Sudarsanakumar 
2011).  
  These interactions highlight the versatility of curcumin in its ability to 
associate with other molecules, but only its antioxidant and Michael acceptor 
functions are expected to contribute significantly to its ability to modulate 
signaling in these proteins. The Michael acceptor capacity and antioxidant effects 
of curcumin however do not account for the many and varied targets identified. 
The chemical mechanisms whereby curcumin is able to affect its proteins targets 
therefore remain to be determined. 
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1.7 Curcumin bioavailability  
 A second conundrum associated with the biological effects of curcumin is 
that efficacy is often demonstrated in tissues that show low to undetectable levels 
of the unconjugated compound. Curcumin is poorly absorbed across the 
gastrointestinal (GI) tract and is extensively metabolized in the liver and 
intestines, accounting for the submicromolar levels of the unconjugated 
compound observed in blood after oral dosage (Holder, Plummer, and Ryan 
1978; Wahlström and Blennow 1978; Hoehle et al. 2006) Yang et al. 
administered 10 mg/kg of curcumin intravenously to rats and reported maximum 
serum levels 0.36 µg/mL after 45 min. A very high oral dose of 500 mg/kg 
curcumin gave only 0.06 µg/mL, and 1 g/kg dose produced a maximum serum 
curcumin level of only 0.5 µg/mL after 45 min. The comparatively low plasma 
levels of curcumin seen after the oral doses support significant first pass 
metabolism of curcumin (Yang et al. 2007). Similar plasma levels of curcumin are 
reported in other animal studies (Holder, Plummer, and Ryan 1978; Pan, Huang, 
and Lin 1999). 
Curcumin was undetectable in the serum in studies in human subjects 
given a single oral dose of 0.5 or 10 g curcumin. Only one of three subjects who 
received a 10 g dose had detectable serum levels of 0.03 to 0.06 μg/mL after 1, 
2, and 4 hours. An increase to a 12 g dose resulted in detectable levels in only 
one of three subjects with comparable serum levels over the same time period 
(Lao et al. 2006). These results are consistent with data from other studies in 
which glucuronide conjugates of curcumin and its reduced metabolites are the 
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predominant form of the compound detected in plasma (Vareed et al. 2008; 
Pawar et al. 2012; Awasthi et al. 2000). 
 Multiple approaches are being employed to improve the uptake of 
curcumin from the gut, including complexes with nanoparticles, liposomes, 
micelles and phospholipids. The studies described above used curcumin-C3 
complex marketed/developed by Sabinsa. Curcumin-C3 is a mixture of the three 
curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin) in a 
patented ratio and is reported to enhance the bioavailability of curcumin. Another 
often-used formulation is meriva curcumin patented by Indena SpA, Milan, Italy. 
The meriva curcumin formulation contains soy lecithin and microcrystalline 
cellulose with an overall curcumin content of 20%. A comparison of 340 mg/Kg 
unformulated curcumin and meriva curcumin corresponding to an equal amount 
of the compound was conducted in rats. In the first group, 99% of curcumin was 
present in plasma as glucuronide conjugates, with the remaining 1% being 
curcumin sulphate and free curcumin. The meriva curcumin group showed 23 
fold increase in glucuronides, but only a 5 fold increase in curcumin (Marczylo et 
al. 2007). Curcumin levels in the plasma therefore remains low, and only 
marginal improvements in efficacy have been reported with these formulations.  
 Even though the low bioavailability is considered the main limitation to the 
clinical efficacy of curcumin, pre-clinical studies in rodents do report efficacy with 
plasma exposures that one would consider sub-therapeutic. Examples include 
systemic effects of dietary curcumin (0.01%–0.25% w/w) in treating inflammatory 
eye disorders (Wang et al. 2011) and glioma in the brain (Perry et al. 2010; Aoki 
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et al. 2007). These effects either suggest extraordinary potency for systemic 
curcumin, or suggest a role for its more abundant metabolites.  
 
1.8 Curcumin metabolism  
 Studies assessing the metabolism of curcumin in rat liver slices, 
microsomes, and cytosol yields octahydrocurcumin, hexahydrocurcumin 
tetrahydrocurcumin and dihydrocurcumin (Hoehle et al. 2006). Thus, the phase I 
metabolism of curcumin involves the successive reduction of the unsaturated 
heptadieneone chain (Figure 1.5). Alcohol dehydrogenase is required for the 
formation of tetrahydrocurcumin and hexahydrocurcumin, the abundant reduced 
metabolites, while unidentified microsomal enzyme(s) catalyze the reduction of 
hexahydrocurcumin to octahydrocurcumin (Hoehle et al. 2006). 
 The reported conjugation metabolites of curcumin are glucuronide and/or 
sulfate conjugates; the major conjugation metabolites were formed in varied but 
significant amounts (Vareed et al. 2008; Ireson et al. 2001). None of the 
postulated cytochrome P450 metabolites (demethylation or hydroxylation) of 
curcumin were detected, suggesting these enzymes are not involved to an 
appreciable extent in curcumin metabolism of curcumin in the liver (Hoehle et al. 
2006). 
 Analyses of curcumin metabolism in vivo are consistent with the in vitro 
data, indicating reduction of the unsaturated heptadienone chain of curcumin and 
subsequent conjugation to glucuronic acid or sulfates (usually inferred after 
hydrolysis with β-glucuronidase and arylsulfatase) forms the major metabolites. 
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The first detailed study on the in vivo metabolism of curcumin was conducted in 
rats by Holder et al. using [3H]-curcumin (Holder, Plummer, and Ryan 1978). 
After an oral dose of 0.6 mg [3H]curcumin, about 90% of the radioactivity was 
detected in the feces, suggesting biliary excretion of curcumin and its 
metabolites. Similar data were obtained when [3H]curcumin was administered 
intravenously. Most of the excretion occurred within the first 24 h of 
administration, with very little compound detected in the tissues beyond 3 days. 
Glucuronide conjugates represented more than 95% of the metabolites 
recovered from the bile. Most of the glucuronide was conjugated to tetra- and 
hexahydrocurcumin. Sulfates accounted for about 2% of the metabolites (Holder, 
Plummer, and Ryan 1978).  
 After oral administration of 8 g curcumin in human subjects, curcumin-
glucuronide and curcumin-sulfate were detected in plasma at 1.5 to 1.7 μM and 
0.21 to 0.35 μM, respectively. Hexahydrocurcumin and hexahydrocurcumin 
glucuronide were also present in minor amounts (Lao et al. 2006). 
 Several studies have also explored the tissue distribution of curcumin. 
Among these are studies conducted by Ravindranath & Chandrasekhara, 
showing that after oral administration of 400 mg of curcumin to rats, only traces 
of the parent compound could be found in tissues such as the liver and kidney. 
After 30 min, about 90% of curcumin was found in the stomach and small 
intestine, but only 1% was present at 24 h, with less than 3% of the curcumin 
found in the tissues. In a similar evaluation of the tissue distribution using 
[3H]curcumin diluted with cold curcumin, radioactivity was detectable in blood, 
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liver, and kidneys after oral administration of 400, 80, or 10 mg of the compound. 
With a high dose of 400 mg [3H]curcumin, large amounts of the radioactivity were 
present in tissues 12 days after dosing. [3H]Curcumin remained in the body for 
72 h to 12 days with doses of 10 mg and 400 mg (Ravindranath and 
Chandrasekhara 1981). 
 
1.9 Chemical instability of curcumin in vitro 
The instability of curcumin at alkaline conditions (pH 7 to pH 10) was 
reported in 1985 by Tonnesen & Karlsen. The reported products of the 
degradation were ferulic acid, vanillin, feruloylmethane, and condensation 
products of feruloylmethane. The products were identified by GC-MS comparison 
with authentic standards.  
A more detailed account of this degradation was later provided by Wang 
et al. The authors showed that curcumin undergoes degradation at alkaline pH in 
aqueous buffer, cell culture medium, and human blood. In 0.1 M phosphate 
buffer at pH 7.2, curcumin degrades rapidly with 90% of the chromophore at 423 
nm disappearing over 10 minutes. Curcumin was more stable in media 
containing 10% serum or in human plasma in which it has a half-life of about 8 h 
(Strimpakos and Sharma 2008; Wang et al. 1997). Curcumin degradation is also 
slower in the presence of thiol-based antioxidants such as glutathione, and 
divalent ions such as Zn2+, Cu2+, Mg2+, and Se2+ (Zebib, Mouloungui, and Noirot 
2010). No appreciable degradation of curcumin occurs below pH 7. 
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.Wang et al. identified vanillin, ferulic acid and feruloyl methane (Figure 
1.6) as minor products of this degradation with the major product tentatively 
identified as trans-6-(4’-hydroxy-3’-methoxyphenyl)-2,4-dioxo-5-hexenal. The 
identification of vanillin, ferulic acid and feruloyl methane was based on retention 
time comparisons with authentic standards. Due to limited sample availability, the 
major product was only tentatively identified based on LC–ESI–MS. Its structure 
FIGURE 1.6 Curcumin metabolism. 
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was inferred based on a molecular weight (MW) of 248, even though the MS 
spectrum showed several more prominent ions at higher m/z values (Wang et al. 
1997). 
Recent studies in our laboratory showed that transformation of curcumin in 
alkaline buffer is an autoxidation, and identified the major reaction products as a 
dioxygenated bicyclopentadione and its two less abundant configurational 
isomers. The chain cleavage products vanillin, ferulic acid and feruloyl methane, 
were not detected in these analyses. (Griesser et al. 2011; Gordon and 
Schneider 2012). We proposed a mechanism for autoxidation of curcumin 
initiated by hydrogen abstraction from one of the phenolic hydroxyls to form a 
phenoxyl radical that rearranges to a reactive quinone methide and carbon 
centered radical. The radical mediates intramolecular cyclization of C2 to C6 to 
give the cyclopentadione ring, and the incorporation of molecular oxygen (O2) 
into the to form the final bicyclopentadione product. This reaction mechanism is 
discussed in detail in chapter 2.  
Curcumin also exhibits poor stability towards irradiation with ultraviolet and 
visible light. Curcumin absorbs strongly in the visible wavelength range (max 
430 nm) making it susceptible to photo-degradation. In ethanol-extracted 
curcumin in the crystalline state, exposure to sunlight over 5 days yielded chain 
cleavage products vanillin (34%), ferulic aldehyde (0.5%), ferulic acid (0.5%) and 
vanillic acid (0.5%) and other unidentified products. The similar analysis using 
methanol-extracted curcumin yielded the same products, but in different 
abundances: vanillin (2%), ferulic aldehyde (0.2%), ferulic acid (0.1%) and 
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vanillic acid (1.5%), suggesting that the crystalline form of curcumin used affects 
the rate of degradation (Khurana and Ho 1988). Under UV (254 nm) irradiation in 
aqueous buffer, 50% of the curcumin chromophore detected at 405 nm 
disappear over 8 h, compared to 36% over 24 h when stored in a dark place. The 
rate of UV induced degradation was also higher with increasing pH, with 70% 
degradation seen in 2 h at pH 8 (Lee et al. 2013).  
The low bioavailability of curcumin, coupled by its chemical instability, has 
led to the notion that metabolites are mediators of some of its effects. To date, 
there is little evidence to support a role for the aforementioned chain cleavage, 
reduced or conjugated metabolites. Our recent discovery that curcumin 
undergoes oxidative transformation to generate the bicyclopentadione through 
reactive intermediates has refueled the hypothesis of metabolites as ultimate 
mediators of these effects. We hypothesize that the oxidative metabolism of 
curcumin contributes to its biological effects. 
 
1.10 Reactive protein thiols as biological sensors. 
The oxidative degradation of curcumin is proposed to progress through 
electrophilic quinone methide and epoxide intermediates to form the final 
bicyclopentadione product (Griesser et al. 2011). Many of the protein targets of 
curcumin are regulated by covalent adduction to electrophiles at reactive 
cysteine residues. Cysteine thiols are a major site of reactivity in proteins and 
show high reactivity towards electrophiles. Many drugs and environmental 
chemicals are metabolized to generate reactive electrophiles that modify proteins 
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and DNA (Dennehy et al. 2006). Cysteine thiols are considered soft electrophiles 
exhibiting the characteristic low electronegativity and high polarizability. 
Electrophiles preferentially react with nucleophiles of comparable 'hardness'. 
Thus, α,β-unsaturated carbonyls, quinones and epoxides, all soft electrophiles, 
show selectivity towards Michael reaction with cysteine thiols (Lopachin and 
Decaprio 2005). This reaction selectivity confers specificity to electrophiles in 
their targeting of cellular proteins for modification.  
 Protein targets of curcumin regulated by reactive cysteines include the 
transcription factor NF-B (Pandey et al. 2007). NF-B is an important target of 
curcumin and plays a prominent role in inflammation and cancer (Valacchi et al. 
2004; S. Singh and Khar 2006). In the resting state, NF-κB lingers in the cystosol 
in complex with its inhibitor B Activation of NF-B ultimately depends on 
phosphorylation of its upstream regulator IκB kinase (IKK). When activated by 
phosphorylation, IKK in turn phosphorylates B to relieve its inhibition of NF-B, 
which is then freed to enter to nucleus (Denk et al. 2001). Electrophilic adduction 
to cysteine 179 in IKK has been shown to prevent its activation leading to the 
inhibition of NF-B (Pandey et al. 2007). Curcumin can interact with IKK to inhibit 
its phosphorylation and prevent the translocation of NF-B to the nucleus 
(Cohen, Veena, Srivatsan, & Wang, 2009). While covalent adduction of curcumin 
to IKK has not been demonstrated, a similar natural phenolic compound, butein, 
was shown to directly modify IKK cysteine residue 179 to inhibit NF-kB (Pandey 
et al. 2007). The electrophilic lipid oxidation product acrolein also adducts to IKK 
at (unidentified) reactive cysteine residues to inhibit NF-B (Valacchi et al., 
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2004). Curcumin, and its more reactive quinone methide and epoxide 
metabolites in particular, could be acting via a similar mechanism. 
 Another example of a curcumin target regulated by reactive thiols is the 
Keap1 protein, which mediates the activation of the transcription factor Nrf2. 
Electrophlic modification of cysteine thiols in Keap1 leads to Nrf2 translocation to 
the nucleus and transcription of antioxidant defense genes. Other examples of 
proteins with reactive thiols are various PPAR phosphatases, peroxiredoxins, 
and thioredoxin (Dennehy et al. 2006). 
 Cysteine thiols are subjected to oxidation by ROS. Oxidized thiols form 
sulfenic (Cys-SOH), sulfinic (Cys-SO2H), and sulfonic acids (Cys-SO3H) 
depending on the degree of oxidation (Cooper et al. 2002; Reddie and Carroll 
2008). The first oxidation product of Cys-SH is the sulfenic acid. Sulfenic acids 
are unstable, reversible, and easily oxidized to sulfinic and sulfonic acids. 
Sulfenic acids exhibit both nucleophile and electrophile properties, and exhibit 
different reactivity compared to thiols (Vaidya, Ingold, and Pratt 2009). Sulfenic 
acids exist only transiently and undergo further oxidation to the sulfinic acid, or 
react with another nucleophilic thiol to form a disulfide bond. The formation of the 
disulfide bond serves as a means of regenerating the native protein through the 
actions of glutaredoxin enzymes (Figure 1.7). Acting as an electrophile, sulfenic 
acids react selectively with a model -diketone, 5,5-dimethyl-1,3-
cyclohexanedione (dimedone) (Poole et al. 2005.). It is therefore likely that 
molecules that share this -diketone, such the bicyclopentadione product of 
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curcumin oxidation, would also adduct to protein sulfenic acids to modulate 
protein signaling.  
 Sulfonic acid is the most highly oxidized and is irreversible. This non-
enzymatic modification of proteins mediates apoptosis, cell migration, 
inflammation, and other cellular processes. The nature of the oxidation is 
controlled by the oxidative state of the cell, or the actions of reducing enzymes 
including families of peroxiredoxin (PRX) that either reduce or promote oxidation 
(Jeong et al. 2011; Wetzelberger et al. 2010).  
 
 
 
FIGURE 1.7 Redox cycling of sulfenic acids. 
 
1.11 Glucuronidation reactions  
 Conjugation with glucuronic acid is the major route of phase-II metabolism 
of curcumin. Glucuronidation involves the direct condensation of a drug with the 
activated form of glucuronic acid, UDP–glucuronic acid (UDPGA). Conjugation 
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with the polar glucuronic acid moiety is an important and common means of 
eliminating drugs from the body (Ritter 2000). As a general rule, drugs are 
lipophilic, distribute readily into the tissues, and are not easily excreted from the 
body. The resulting drug-glucuronide conjugate is much more hydrophilic and is 
more readily excreted in the urine and bile. Furthermore, glucuronidation is 
generally a deactivation reaction generating less biologically and chemically 
active metabolites. A wide variety of chemicals are subjected to glucuronidation, 
with the common feature being the presence of an appropriate functional group (-
NH, -OH, -SH or -COOH). Glucuronidation occurs in the liver, small intestine, and 
colon (Ritter 2000; Johnson and Mukhtar 2007).  
  The re-formation of the unconjugated form of the drug from the O-
glucuronide conjugates is achieved through the action of -glucuronidase 
enzymes located in lysosomes of most cell types and in gut microbes (Sperker et 
al. 2000; B Sperker, Backman, and Kroemer 1997). Glucuronide conjugates are 
often secreted through the bile into the intestine where they are hydrolyzed to 
reform the aglycone compound and then reabsorbed. This process, called 
enterohepatic circulation, serves to increase exposure to the parent drug. Re-
absorption of the unhydrolyzed drug is otherwise very inefficient. Tissue specific 
hydrolysis of glucuronide conjugates has been described in cancers. In these 
tissues, there is increased β-glucuronidase activity, resulting in secretion of the 
enzyme into the extracellular space where hydrolysis of the glucuronide 
conjugates occurs. The highly hydroplilic glucuronides do not penetrate the cell 
and may not be otherwise subjected to the actions of the enzyme (Weyel et al. 
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2000). Furthermore, the action of -glucuronidases in tumors can selectively 
activate glucuronide 'prodrugs' into the active aglycone specifically at the tumor 
site, thereby reducing systemic exposure to the compound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
1.2. Specific Aims 
 
My research project is based on the discovery in our lab that curcumin 
undergoes a previously unrecognized oxidative transformation to generate a 
novel bicyclopentadione derivative of curcumin as the major product. Initial 
studies into the mechanism of transformation suggest a reaction via reactive 
quinone methide and epoxide intermediates to form the final bicyclopentadione 
products. However, studies on the reaction mechanism were incomplete, and 
other products of the transformation remained to be identified. 
Our finding that curcumin undergoes oxidative metabolism in vitro to 
generate bioactive compounds could be a major step forward understanding how 
curcumin exerts its chemopreventive and therapeutic effects. Furthermore, 
oxidative metabolites of curcumin could represent new lead compounds with 
improved efficacy to overcome the many therapeutic limitations of curcumin. 
 
The specific aims of the project were as follows: 
Specific Aims:  
a) To identify the products of curcumin oxidative transformation. 
b) To determine the mechanism of formation of curcumin oxidative products.  
c) To assess the oxidative transformation of curcumin-glucuronide  
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Chapter 2 
 
MECHANISTIC STUDIES INTO THE OXIDATIVE TRANSFORMATION OF 
CURCUMIN 
 
2.1 Introduction 
 Curcumin is a naturally occurring chemopreventive agent isolated from the 
rhizome of the Curcuma longa plant. Curcumin possesses anti-inflammatory, 
anti-oxidant, and anti-cancer properties in vitro and in animal models by 
modulating up to 100 cellular targets, but its chemical mechanisms of action are 
still unclear (Goel, Kunnumakkara, and Aggarwal 2008). Curcumin exhibits very 
low bioavailability resulting from poor absorption and extensive metabolism that 
renders it undetectable in most tissues after oral dosage (Vareed et al. 2008; 
Metzler et al. 2013; Pan, Huang, and Lin 1999). Curcumin undergoes metabolic 
glucuronidation and sulfation, as well as reduction of its dienone double bonds 
(Ireson et al. 2001). In vitro, curcumin undergoes spontaneous degradation at 
physiological pH (Wang et al. 1997). Attempts at identifying the products of the 
pH dependent transformation of curcumin have proved elusive, with only minor 
products vanillin, ferulic acid, and feruloyl methane identified. The major product 
was recently identified as a dioxygenated bicyclopentadione by our group 
(Griesser et al. 2011). 
The low bioavailability of curcumin has been credited for the lack of 
therapeutic efficacy in past clinical trials. Thus, overcoming the low bioavailability 
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of curcumin has been explored as a route towards improving its clinical efficacy 
(Pawar et al. 2012). Recent research in the field has led to significant 
improvements in the bioavailability of curcumin, mainly through developing 
complex formulations involving encapsulation by phospholipid or nanoparticles. 
However, only marginal effects on clinical efficacy have been reported so far with 
these novel formulations (Belcaro et al. 2010; Marczylo et al. 2007).  
As an alternative to the ‘bioavailability’ approach, we have pursued 
research aimed at understanding the chemical basis for the pleiotropic effects of 
curcumin. Questions about the chemical bases for the effects of curcumin are 
pertinent given its virtual absence from organs, such as the brain, where efficacy 
have been demonstrated (Aoki et al. 2007). Moreover, curcumin mediates its 
effects by targeting up to 100 different cellular targets, a remarkable achievement 
for any one molecule. With these discrepancies it became hard to attribute all the 
biological effects to the parent curcumin and metabolites are implicated as 
ultimate mediators of some of these effect (Shen and Ji 2009; Shen and Ji 2012). 
There is little evidence to support major roles for the known metabolites 
(conjugation, reduction, or chain cleavage products) in the biological activities of 
curcumin.  
Our discovery that curcumin undergoes oxidative transformation to 
generate novel products has refueled the hypothesis of metabolites as ultimate 
mediators of curcumin's effects. Consistent with the earlier studies on curcumin 
reaction in buffer, we found that curcumin degrades rapidly at pH 7.5 (Wang et 
al. 1997; Griesser et al. 2011). Contrary to earlier reports, however, we found 
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that the major reaction is an autoxidation to generate a dioxygenated 
bicyclopentadione as the final product (Figure 2.1), with the chain cleavage to 
form vanillin a minor reaction. 
 
 
Spectrophotometric analysis of curcumin autoxidation showed the 
disappearance of its 430 nm chromophore, suggesting disruption of the 
conjugated system along the heptadienone linker. A new chromophore at 263 nm 
is formed concomitantly with the disappearance of curcumin (Wang et al. 1997; 
Griesser et al. 2011). None of the isolated products of curcumin autoxidation 
showed a 263 nm chromophore, suggesting the existence of other yet 
unidentified products. HPLC-UV and LC-ESI-MS showed one major peak for the 
bicyclopentadione and two minor peaks identified as its configurational isomers. 
The molecular weight (MW) of 400 supports the incorporation of two oxygen 
atoms (MW 32) during degradation of curcumin (MW 368). The 
bicyclopentadione structure was ultimately confirmed after 1D and 2D NMR 
analyses. The bicyclopentadione is the same compound tentatively identified by 
Wang et al as trans-6-(4’-hydroxy-3’-methoxyphenyl)-2,4-dioxo-5-hexenal, since 
Figure 2.1 Autoxidation of curcumin generates a dioxygenated bicyclopentadione as 
the major product. 
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both compounds shared identical MS2 spectra (Wang et al. 1997; Griesser et al. 
2011). 
 Prompted by the structural elucidation of the bicyclopentadione product, 
analyses into the incorporation of oxygen into the molecule were performed in an 
oxygen electrode. The data showed the consumption of molecular oxygen at a 
rate equivalent to the degradation of curcumin, suggesting the incorporation of 
molecular oxygen (O2) into the molecule during the reaction. It was further 
determined that COX-2 catalyzes the same transformation of curcumin at its 
peroxidase active site (Griesser et al. 2011). Studies conducted by other groups 
on the interaction of COX-1 peroxidase with other natural phenols, e.g. 
resveratrol, indicate that phenolic hydroxyls serve as an electron source during 
catalysis by peroxidases and are thereby oxidized to a phenoxyl radical 
(Szewczuk et al. 2005). Thus, catalysis by peroxidases, as well as the alkaline-
pH dependence of the autoxidative transformation, led to a proposed mechanism 
of curcumin transformation initiated by H-abstraction from one of its phenolic 
hydroxyls to form a phenoxyl radical. Curcumin is completely conjugated 
therefore the phenoxyl radical is delocalized and migrates into the heptadieneone 
chain at C2, forming a quinone methide in the process. The cyclopentadione ring 
of the bicyclopentadione is formed from the radical at C2 undergoing 5-exo 
cyclization onto C6. The newly formed radical at C6 mediates the incorporation of 
molecular oxygen O2 into the molecule that progresses to form the 
bicyclocpentadione. LC-MS analysis of the bicyclopentadione formed in H218O 
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suggest that only one of the oxygen incorporated from O2 is retained in the 
molecule, and the other replaced with oxygen from H2O (Griesser et al. 2011). 
 The main aims of my project are to determine the complete profile of 
products formed during curcumin autoxidative transformation, and to elucidate 
their mechanism of formation. I used radiolabeled [14C2]curcumin in autoxidation 
studies to isolate and structurally identify four intermediates and six novel 
products formed from curcumin oxidative transformation. Our studies allowed us 
to refine and expand what was known from the previously proposed reaction 
mechanism.  
 
2.2 Materials and Methods 
 
2.2.1 Materials 
 Curcumin was synthesized as previously described (Pabon 1964). A 5 mM 
stock solution of curcumin in ethanol was prepared on the day of the 
experiments. Oxygen-18 labeled water (97 atom-% 18O) was obtained from 
Isotec. Oxygen-18O2 (99 atom-% 18O) and deuterium oxide (D, 97%) were from 
Sigma. [14C]Methyl iodide (2 mCi/mmol) was from American Radiolabeled 
Chemicals, Inc., St. Louis, MO. [d3]Methyl iodide (99.5%) acetylvanillin, 3,4-
dihydroxybenzaldehyde, 3,4,dimethyl-benzaldehyde and all other reagents were 
from Sigma. Chelex-100 resin was from Bio-Rad, Hercules, CA. 
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2.2.2 Synthesis of isotopic analogs of vanillin and curcumin 
 
dihydroxy-
benzaldehyde
HO
H
O
NaOH/
MeOH/
DMA
14CH3I
HO
H
O
[14C]vanillin
HO H3CO
 
FIGURE 2.2 Synthesis of [14C]vanillin 
 
[14C]Vanillin 
 3,4-Dihydroxybenzaldehyde (15 mg, 0.1 mmol) was dissolved in 4 M 
methanolic NaOH (50 µl) and diluted with dimethylacetamide (200 µl). [14C]Methyl 
iodide (7 mg, 0.05 mmol, 2 mCi/mmol) in toluene (100 µl) was added dropwise to 
the solution. The reaction was stirred for 2 h, acidified with 1 M HCl, and 
extracted three times with 500 µl dichloromethane (Figure 2.2). The solvent was 
evaporated, and the product was isolated using RP-HPLC (Method A) to yield 
3.5 mg [14C]vanillin (52 μCi, 52% radiochemical yield; purity 98% by HPLC). The 
identity of [14C]vanillin was confirmed by comparison of its RP-HPLC retention 
time and UV spectra with an authentic standard. LC-MS analysis was not 
performed in order to avoid contamination of the instrument with radioactive 
material. 
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[14C2]Curcumin 
 
 
FIGURE 2.3 Synthesis of [14C2]curcumin. 
 
 Boron oxide (20 mg, 0.3 mmol) and acetylacetone (40 µl, 0.4 mmol) were 
stirred for 16 h to form a white paste. An aliquot (20 µl) of the paste dissolved in 
ethyl acetate (360 µl) was added to 3.5 mg [14C]vanillin (0.03 mmol, 52 μCi) 
dissolved in tributyl-borate (21 µl). The mixture was stirred for 5 min after which a 
10% dilution of butylamine in ethyl acetate (2 µl) was added every 10 min for 
40 min. The reaction was stirred for 16 h overnight. The next day, 0.4 M HCl 
(100 µl; heated to 60 ºC) was added to the reaction and stirred for 1 h (Figure 2.3). 
[14C2]Curcumin was extracted into ethyl acetate (4 × 200 µl) and purified using 
RP-HPLC (Method A) to yield 1.2 mg purified [14C2]curcumin (13 μCi; 
4 mCi/mmol; 25% radiochemical yield; purity 97% by HPLC).1H NMR (CD3OD, 
600 MHz): δ = 3.91 (s, 6H), 5.97 (s, 1H), 6.64 (d, 2H, J = 15.0 Hz), 6.82 (d, 2H, 
J = 7.9 Hz), 7.1 (d, 2H, J = 7.5 Hz), 7.22 (s, 2H), 7.57 (d, 2H, J = 15.0 Hz) ppm. 
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[d3]Vanillin 
 [d3]Vanillin was prepared as described for [14C]vanillin starting from 3,4-
dihydroxybenzaldehyde (50 mg, 0.35 mmol) and [d3]methyl iodide (50 mg, 
0.35 mmol) in toluene (100 µl). The product was isolated using RP-HPLC 
(Method B) to yield [d3]vanillin (26 mg; 47% yield; purity 91% by HPLC). LC-MS: 
154.1 ([M − H]−). 1H NMR (CD3OD, 600 MHz): δ = 5.28 (s, 1H), 6.77 (d, 1H, 
J = 8.1 Hz) , 6.86 (dd, 1H, J = 8.1; 1.8 Hz) , 6.98 (d, 1H, J = 1.8 Hz), 9.75 (s, 1H) 
ppm. 
 
3’-OCD3,4”-O-methylcurcumin 
 3’-OCD3,4”-O-methylcurcumin (Figure 
2.4) was from a 1:1 reaction [d3]vanillin and 
3,4-dimethoxybenzaldehyde. Boron oxide 
(20 mg, 0.3 mmol) and acetylacetone (40 µl, 
0.4 mmol) were stirred for 16 h to form a 
white paste. This is added to 1:1 mixture of [d3]vanillin and 3,4-
dimethoxybenzaldehyde (20mg, 0.9 mmol each) dissolved in tributyl-borate 
(200 µl) and ethyl-acetate (300 µl). The mixture was stirred for 5 min after which 1 
µl of butylamine was added every 10 min for 40 min. The reaction was stirred for 
16 h overnight. The next day, 0.4 M HCl (500 µl; heated to 60 ºC) was added to 
the reaction and stirred for 1 h. 3’-OCD3,4”-O-methylcurcumin was extracted into 
ethyl acetate (4 × 200 µl) and purified using RP-HPLC (Method A) LC-MS: 416 
([M − H]−). 
FIGURE 2.4 Structure of 3’-
OCD3,4”-O-methylcurcumin 
OCH3HO
OH O
OCH3D3CO
3'-OCD3,4"-O-methylcurcumin
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[13C5]Curcumin 
 
 
FIGURE 2.5 Synthesis of [13C5]acetylacetone 
 
 [13C3]Acetone (120 µl, 2 mmol) and [13C4]acetic anhydride (500 µl, 5 mmol) 
were placed in a 1-ml reaction vial and cooled in an ice-salt bath. Boron 
trifluoride diethyl etherate (400 µl, 3 mmol) was added slowly over the course of 
3 min. The reaction was stirred for 4 h and then poured into 3 ml of 10 M sodium 
acetate heated to 80 ºC. The reaction was extracted twice using 500 µl 
dichloromethane to yield 12 mg (0.1 mmol; 5% yield) [13C5]acetylacetone (Figure 
2.5). [13C5]Curcumin was prepared as described for [14C2]curcumin starting from 
boron oxide (47 mg, 0.7 mmol) and [13C5]acetylacetone (12 mg) dissolved in 
dichloromethane (100 µl). Vanillin (250 mg), tributylborate (800 µl) in 800 µl ethyl 
acetate, and butylamine (5 µl) were added. The products were loaded onto a 2-g 
Supelco DSC-18 cartridge in 30% acetonitrile and eluted using 100% acetonitrile. 
[13C5]curcumin was purified using RP-HPLC (Method A; 51% yield; purity 92% by 
HPLC). LC-MS: 372.2 ([M − H]−).1H NMR (CD3OD, 600 MHz): δ = 3.91 (s, 6H), 
5.97 (s, 1H), 6.64 (d, 2H, J = 15.7 Hz), 6.82 (d, 2H, J = 8.1 Hz), 7.1 (dd, 2H, 
J = 8.3; 1.8 Hz), 7.21 (d, 2H, J = 1.7 Hz), 7.58 (d, 2H, J = 15.7 Hz) ppm. 
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2.2.3 Analytical procedures for synthesized compounds 
RP-HPLC  
 Products were analyzed and purified by RP-HPLC using an Agilent 1200 
series diode array system equipped with a Waters Symmetry C18 5-µm column 
(4.6 × 250 mm). The column was eluted with a linear gradient of 
MeCN/H2O/HOAc 20/80/0.01 to 80/20/0.01 (by vol.) over 20 min and a flow rate 
of 1 ml/min (Method A). Semi-preparative RP-HPLC using a Waters Symmetry 
C18 column (300 × 19 mm) was eluted with a solvent of MeOH/H2O/HOAc 
(40/60/0.01, by vol.; Method B) or MeCN/H2O/HOAc (55/45/0.01, by vol; Method 
C) or MeOH/H2O/HOAc (75/25/0.01, by vol.; Method D) at a flow rate of 
10 ml/min.  
 
LC-MS 
 LC-MS was performed using a Thermo LTQ ion trap instrument equipped 
with an electrospray ionization interface. The instrument was operated in the 
negative ion mode, and mass spectra were acquired at a rate of 2 s/scan. The 
settings for the heated capillary (300 °C), spray voltage (4.0 kV), spray current 
(0.22 μA), auxiliary (37 mTorr), and sheath gas (16 mTorr) were optimized using 
direct infusion of a solution of curcumin (20 ng/µl) in MeCN/H2O 95/5, by volume, 
containing 10 mM NH4OAc. Samples were introduced using a Waters Symmetry 
Shield C18 3.5-µm column (2.1 × 100 mm) eluted with a gradient of MeCN/H2O 
(5/95, by volume, containing 10 mM NH4OAc) to MeCN/H2O (95/5, by volume, 
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containing 10 mM NH4OAc) over 10 min followed by 3 min of isocratic elution and 
re-equilibration in the starting solvent (Method E).  
 
NMR 
 NMR spectra were recorded using a Bruker AV-II 600 MHz spectrometer 
equipped with a TCI cryoprobe. Chemical shifts are reported in ppm relative to 
the non-deuterated solvent peak of methanol-d4 (δ = 3.34 ppm). 
 
2.2.4 Oxidation of curcumin in vitro 
Curcumin autoxidation 
 Curcumin was diluted to a concentration of 50 μm in 50 mM NaPO4 buffer 
pH 7.5 for 20 minutes (or as indicated). For extraction, the sample was loaded 
onto a preconditioned 30 mg Waters HLB cartridge. After washing with water the 
cartridge was eluted with 2x 500 μl MeOH. The solvent was evaporated under a 
stream of nitrogen and the residue dissolved in acetonitrile for RP-HPLC 
analysis. For product identification, 20x 50 ml reactions were conducted in 
parallel. Extraction was performed as described above. For autoxidation of 
[14C2]curcumin, 250k cpm was added to 500 l buffer (30 uM curcumin). 250 l of 
the crude reaction were injected at 30 minutes and 2 hrs. 
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Reaction progress 
 Products 6a and 6b were isolated from 2 ml curcumin autoxidation 
reactions at 20 min.  The products were dissolved in 10 mM NH4OAc buffer pH 
7.4 and an aliquot analyzed using LC-MS at 15 or 45 min intervals over 6 hrs. 
 
Preparation of 18O labeled metabolites 
 Autoxidative transformation of curcumin was conducted using 100 μl of 
buffer. 5 μl of a 1 M stock solution of NH4OAc buffer pH 8 was diluted with 95 μl 
of H218O (97 atom-% 18O). Curcumin, 2 μl from a 5 mM stock solution in ethanol, 
was added, and the reaction was allowed to proceed for 30 min. A reaction using 
unlabeled H2O was conducted in parallel. 
 For NMR analysis, the autoxidative reaction was scaled up to 100 ml in 10 
mM NH4OAc buffer pH 8. After 20 min, the reaction is loaded onto a 2 mg HLB 
cartridge and eluted with MeOH. The MeOH solution is evaporated under a 
stream of nitrogen and re-dissolved in 500 μl H218O after 6 h, the reaction is 
acidified and before RP-HPLC purification of the bicyclopentadiones. 
 
Preparation of deuterium-labeled metabolites 
 For LC-MS analysis, autoxidative transformation of curcumin was 
conducted using 100 μl of buffer. 5 μl of a 1 m stock solution of NH4OAc  buffer 
pH 8 was diluted with 95 μl of D2O (D, 97%). Curcumin, 2 μl from a 5 mM stock 
solution in ethanol was added and the reaction was allowed to proceed for 30 
min. A reaction using unlabeled H2O was performed in parallel.  
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 For NMR analysis, the autoxidative reaction was scaled up to 100 ml in 
ammonium acetate buffer pH 8. After 20 minutes (when the spiroepoxides 7 are 
the abundant products) the reaction is loaded onto a 2 mg HLB cartridge and 
eluted with MeOH. The MeOH solution was evaporated under a stream of 
nitrogen and re-dissolved in 500 l D2O at room temperature. After 6 h, the 
reaction is acidified before RP-HPLC purification of the bicyclopentadiones.  
 
Synthesis of diguaiacol standard 
 Guaiacol (2 mg, 0.02 mmol) was dissolved to a final concentration of 16 
mM in 1 ml of a 10 mM pyrophosphate buffer containing H2O2 (0.35 mM), GSH 
(1.6 mg, 5mM) and manganase acetate (0.04 mg, 1mM). The reaction was 
allowed to proceed at room temperature for 12 h before extraction on a 
preconditioned 50 mg Waters HLB cartridge eluted with MeOH. The sample was 
analyzed on RP-HPLC using a Waters Symmetry C18 5-μm column (4.6 × 250 
mm) eluted with a gradient of 20% MeCN to 80% MeCN in 0.01% aqueous acetic 
acid over 20 min and the diguaiacol product, eluting at retention time 12 min, 
isolated for LC-MS analysis. LC-MS: 245 ([M − H]−). 
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2.2.5 Analytical procedures 
HPLC Analysis 
 The transformation reactions were analyzed using a Waters Symmetry 
C18 5-μm column (4.6 × 250 mm) eluted with a gradient of 20% MeCN to 80% 
MeCN in 0.01% aqueous acetic acid over 20 min followed by 10 min of isocratic 
elution. To isolate individual metabolites, 2% or 10% MeCN in NH4C2H3O2 pH 7.5 
buffer mobile phase is used. All samples run at flow rate of 1 ml/min. Elution of 
the products was monitored using an Agilent 1200 diode array detector. 
  
LC-MS Analysis 
 For LC-MS analyses a Finnigan TSQ Quantum triple quadrupole MS 
instrument equipped with an electrospray interface was used. The instrument 
was operated in the negative ion mode, and mass spectra were acquired at a 
rate of 2 s/scan. The heated capillary was set at 300 °C, and the spray voltage 
was set at 4.4 kV. For LC-MS analysis of oxygen incorporation from 18O-buffer 
(MSn analyses), a Thermo Finnigan LTQ ion trap instrument was used. The 
settings for the heated capillary (300 °C), spray voltage (4.0 kV), spray current 
(0.22 μA), auxiliary (37 mTorr) and sheath gas (16 mTorr) were optimized using 
direct infusion of a solution of curcumin (20 ng/μl) in MeCN /H2O 95/5, by vol., 
containing 10 mm NH4OAc. Samples were introduced into both instruments using 
a Waters Symmetry Shield C18 3.5-μm column (2.1 × 100 mm) eluted with 
acetonitrile/water (3/97, by vol., containing 10 mm NH4OAc) isocratic over 20 
min. 
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NMR 
 Samples were dissolved in 150 μl of methanol-d4 in a 3 mm tube, and the 
NMR spectra were recorded using a Bruker DRX 600 MHz spectrometer 
equipped with a cryoprobe. Chemical shifts are reported in ppm relative to 
residual non-deuterated solven peakt (δ 3.30 for methanol-d4). The pulse 
frequencies for the H,H-COSY, HSQC, and HMBC experiments were taken from 
the Bruker library. The spectra were acquired at 284 K. 
 
2.3 Results 
 
2.3.1 Spectrophotometric analysis of curcumin oxidation 
 Spectrophotometric analysis of curcumin autoxidation in phosphate buffer 
(10 mM, pH 7.4) shows the fast disappearance of the curcumin chromophore at 
λmax 430 nm within 10 min, giving rise to product(s) with prominent absorbance 
at 263 nm (Figure 2.6A). The 263 nm chromophore is formed concomitantly with 
the disappearance of curcumin and then decreased slowly over the next 45 min 
(Figure 2.6B). Further studies showed that the 263 nm chromophore will 
disappear slowly over 2 h with about 50% of that chromophore persisting over 
time, suggesting the presence of both stable and intermediate species (data not 
shown).  
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2.3.2 RP-HPLC analysis of curcumin oxidation 
 The dioxygenated bicyclopentadiones were previously identified as 
products of curcumin autoxidation. (Griesser et al. 2011). Spectrophotometric 
and HPLC analyses of the reaction suggest the formation of additional reaction 
products bearing prominent 263 nm absorbance. Furthermore, the complex 
structure of the bicyclopentadione suggests the involvement of multiple reaction 
intermediates during its formation. In this study, I set out to determine a complete 
profile of products formed from curcumin autoxidation. To this end, I synthesized 
[14C2]curcumin in which the radiolabel is inserted into the inert methoxy groups, 
and used it as a tracer in RP-HPLC analysis. 
 An autoxidation reaction of [14C2]curcumin was analyzed on RP-HPLC 
with diode array and in-line radioactivity detection at 45 min, without extraction. 
The radio-chromatogram, presented in Figure 2.7, shows unreacted curcumin 
eluting at 26 min, and the main bicyclopentadione product 8a and its isomers 8b, 
AU
Time (min)
0 4010 20 30
0
1.50
0.75
products (263) nm
curcumin (425 nm)
1.6
0
0.8
AU
oxidation
Products
Wavelength (nm)
220 300 400 500 600 700
curcumin
FIGURE 2.6: UV/VIS analysis of curcumin autoxidation. (A) The reaction is scanned
from 700-220 at t=0 min and t=10 min. (B): Time drive analysis of curcumin
autoxidation, monitoring 430 nm (curcumin) and 263 nm (oxidized curcumin) over 45
min. 
A B 
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c eluting at 17 and 18 min respectively, substantiating our previous publication 
designating the bicyclopentadione as major product of this reaction (Griesser et 
al. 2011). The chromatogram further shows a series of more polar peaks 1-7 and 
9 that were not previously identified. The most polar of the products (1-4) were 
collected as a group and further resolved into 5 distinct peaks (Figure 2.6B). 
Peak 7 represents diastereomeric isomers (7a, b) that were not resolved on this 
system.  
 
 
 
 
 
 
 
 
 
 There are several factors that made isolation of these metabolites 
unsuccessful until now. The unusual polarity of the metabolites made extraction 
from aqueous buffer difficult and hinders their detection by HPLC due to very 
FIGURE 2.7 (A): Separation of [14C2]curcumin autoxidation products by RP-HPLC. The 
[14C2]curcumin stock solution (3 mM in ethanol) was diluted to a final concentration of 5 μM in
300  l Pi buffer. After 50 min incubation at room temperature, a 100 μl aliquot was injected on
HPLC and eluted with a 10% MeCN in NH4OAc pH 7.5 isocratic for 10 min, followed by linear 
gradient to 80% MeCN over 20 min. The effluent was monitored by radio-detection. (B) The 
group of peaks 1-4 was re-injected on 2% MeCN for further separation. 
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early elution times. Also, compounds 6 and 7 are acid labile and do not survive 
acidification during typical workup and HPLC analysis. 
 
2.3.2 Identification of curcumin oxidation products 
 To obtain a sufficient quantity of the compounds for NMR analysis, large 
scale curcumin autoxidation reactions were performed and each novel product 
(2-7 and 9) isolated for further structural analysis using LC/ESI/MS, ESI/HR/MS 
(summarized in Table 2 of the Appendix) and a combination of 1H, COSY, HSQC 
and HMBC and NOESY NMR analyses (summarized in Table B1-8 of the 
Appendix). Peak 1 contained multiple putative cleavage products (based on LC-
MS analysis) that were not sufficiently abundant for complete structural 
characterization by NMR. 
 The structures of 2 - 9 are presented in Figure 2.8. All the novel products 
have the characteristic cyclopentadione ring formed of C2 to C6 found in the 
bicyclopentadione product 8 and incorporate oxygen atoms at C1 and C7. The 
exceptions are 5 that does not incorporate oxygen but instead has a carbon-
carbon bond between C1 and C7, and 9 that is diguaiacol.  
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Product 2a, asymmetrical dihydroxy-cyclopentadione 
 Product 2a is highly polar dihydroxy-cyclopentadione derivative, and is the 
asymmetrical analog of 2b. It was eluted at 9 min (Figure 2.7). 
 ESI/HR/MS analysis in negative mode of 2a showed m/z 401.1249. 2a is 
nominally a 2H reduction product of 3. MS2 analysis (product ions of m/z 401) 
yielded these major fragment ions: m/z 401 ([M-H]-); 249 (base ion); and 151.  
 1H NMR spectra showed 11 proton and 2 MeO peaks. Six of the protons, 
at 7.0 - 6.5 ppm belonged to the phenolic moiety, suggesting the rings are in the 
FIGURE 2.8 Products of curcumin autoxidative transformation. 
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phenolic form. The proton–proton cross-peaks observed in the COSY analysis 
supported our assignment of H1, H2, H6 and H7 as being part of the same spin 
system, and H4 as an isolated proton. 
 The HSQC signals between 144 and 146 ppm substantiated four sp2 
quaternary carbons attached to oxygen atoms. H1 and H7 are both sp3 
hybridized and connected to oxygen, with shifts of 73 ppm and 77 ppm 
respectively. Since H4 is a singlet at 3.84 ppm, we concluded that in the β-diketo 
moiety exists in a keto- enol form. HMBC crosspeaks between each MeO peak 
and C3' or C3" allowed for their assignment to the different aromatic rings.  1H 
and 13C NMR chemical shifts and characteristic couplings are summarized 
in Table B1. 
 
Product 2b, symmetrical dihydroxy-cyclopentadione 
 Product 2b is a highly polar dihydroxy-cyclopentadione derivative, and is 
the symmetrical analog of 2a. It was eluted at 19 min (Figure 2.7) 
 ESI/HR/MS analysis in negative mode of the metabolite 5 showed m/z 
401.1261. MS2 analysis of product 2b (product ions of m/z 401) yielded these 
major fragment ions: m/z 401 ([M-H]-), 249; and 151. 
 1H NMR spectra showed 5 proton and 1 MeO peaks, representing half the 
symmetrical molecule. Three of the protons, at 7.0 - 6.50 ppm, belonged to the 
phenolic moieties. H1/H7 and H2/H6 are sp3 hybridized with shifts of 4.55 ppm 
and 2.64 ppm respectively. A proton peak for H4 was not seen presumably due 
to rapid exchange with deuterium. 
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 The HSQC signals at 144 pmm and 147 ppm substantiated four sp2 
quaternary carbons attached to oxygen atoms. The 72 ppm peak for C1/C7 and 
51 ppm peak for C2/C6 supports our conclusion that they are all sp3 hybridized, 
with C1/C7 connected to any oxygen. 1H and 13C NMR chemical shifts and 
characteristic couplings are summarized in Table B2. 
 
Product 3, hemiketal cyclopentadione 
 Product 3 is a highly polar hemiketal-cyclopentadione derivative, and 
exists in equilibrium with its hydroxy-keto 4. It was eluted at 28 min (Figure 2.6). 
 ESI/HR/MS analysis of 3 showed m/z 399.1084 representing an increase 
of 32 amu compared with that of curcumin. MS2 analysis (product ions 
of m/z 399) yielded these major fragment ions: m/z 399 ([M-H]-); 247 (base ion); 
355; 313; and 151.  
 1H NMR spectra showed 10 proton and 2 two MeO peaks. Six protons, at 
7.0 - 6.2 ppm, occurred in the aromatic region of the spectra, suggesting the 
rings are in the phenolic form. The proton–proton cross-peaks observed in the 
COSY analysis supported the assignment of H1, H2 and H6 as being part of the 
same spin system, and H4 as an isolated proton. No proton was seen at C7. 
 The HSQC signals between 143 and 150 ppm substantiated four sp2 
quaternary carbon atoms attached to oxygen atoms. C1 is connected to an 
oxygen, as suggested by its chemical shift of 70.0 ppm. On the basis of the 104.2 
ppm chemical shift for C4, and the singlet peak for H4 (5.04 ppm), we concluded 
that in the β-diketo moiety exists keto-enol configuration. HMBC crosspeaks 
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between each MeO peak and C3' or C3" allowed for their assignment the 
different aromatic rings. No coupling into C3, C5 or C7 was observed and their 
chemical shifts were not determined 1H and 13C NMR chemical shifts and 
characteristic couplings are summarized in Table B3. 
 
Product 4, hydroxy-keto -cyclopentadione 
 Product 4 is a highly polar keto-hydroxy cyclopentadione derivative, and 
exists in equilibrium with its hemiketal 3. It was eluted at 36 min (Figure 2.6). 
 ESI/HR/MS analysis of 4 in negative ion mode showed m/z 399.1099 
representing an increase of 32 amu compared with that of curcumin. MS2 
analysis (product ions of m/z 399) yielded these major fragment ions: m/z 399 
([M-H]-); 247 (base ion); 355; 313; and 151.  
 1H NMR spectra showed 9 proton and 2 MeO peaks. Six protons, at 7.40 - 
6.50 ppm, belonged to the phenolic moieties. The proton–proton cross-peaks 
observed in the COSY analysis supported the assignment of H1, H2 and H6 as 
being part of the same spin system, and H4 as an isolated proton. No proton was 
seen at C7.  
 The HSQC signals between 144 and 151 ppm substantiated four sp2 
quaternary carbons attached to oxygen atoms. C1 is bonded to an hydroxyl 
group, with chemical shift of 69.6 ppm. The C2 to C6 bond was determined from 
their (J2) coupling in the HMBC. No proton peak was observed for H4, 
presumably due to rapid exchange for deuterium in the NMR solvent. No 
coupling into C3, C5, C4 or C7 was observed and their chemical shifts were not 
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determined. 1H and 13C NMR chemical shifts and characteristic couplings are 
summarized in Table B4. 
 
Product 5, cyclobutane-cyclopentadione 
 Product 5, a highly polar cyclobutane cyclopentadione eluting at 6 min 
(Figure 2.7), does not incorporate oxygen. 
 ESI/HR/MS analysis of 5 in negative ion mode showed accurate molecular 
ion peak at  m/z 367.1195, matching that of curcumin. MS2 analysis showed the 
existence of precursor ion ([M-H]-) at m/z = 367, and major fragment ions at 217 
(base ion), 271, and 173. 
 1H NMR spectra showed 6 proton and 1 MeO peaks, representing half the 
symmetrical molecule. Three of the protons, at 6.60 - 6.40 ppm, belonged to the 
phenolic moiety and suggested an aromatic confirmation of both rings. H1/H7 
and H2/H6 are sp3 hybridized with chemical shifts of 3.76 ppm and 3.34 ppm 
respectively. H4 is a singlet at 4.7 ppm. The proton–proton cross-peaks observed 
in the COSY analysis supported the assignment of H1/H7 and H2/6 as 
neighboring protons (J=3.18), and H4 as an isolated proton. 
 The HSQC signals at 144 ppm and 147 ppm correspond to the four sp2 
quaternary carbons attached to oxygen atoms in the aromatic rings. The 46 ppm 
and 47 ppm shifts for C1/C7 and C2/C6, respectively, support our conclusion that 
they are all sp3 hybridized and are not connected to oxygen. On the basis of the 
104.2 ppm chemical shift for C4, and the singlet peak for H4 (4.76 ppm), we 
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concluded that in the β-diketo moiety exists keto-enol configuration. 1H and 13C 
NMR chemical shifts and characteristic couplings are summarized in Table B5. 
 
Products 6a and 6b, spiro-epoxide-cyclopentadiones 
 Products 6a and 6b are diastereomeric spiroepoxy cyclopentadiones 
eluting at 10 min (Figure 2.7). 
 ESI/HR/MS analysis in negative ion mode of products 6a and 6b 
showed m/z 399.1088 and 399.1086, respectively,  representing an increase of 
32 amu compared with that of curcumin. MS2 analysis showed the existence of 
precursor ion ([M-H]-) at m/z = 399 and major fragments at 259 (base ion), 355, 
and 315. 
 1H NMR spectra of 6a showed 11 proton and 2 two MeO peaks. Only 5 
protons occurred in the aromatic region of the spectra, with H2' shifted upfield to 
5.25 ppm indicating that the R' ring is no longer aromatic. The proton–proton 
cross-peaks observed in the COSY analysis supported the assignment of H1, 
H2, H6 and H7 as being part of the same spin system, with H4 an isolated 
proton. H7, at 5.20 ppm, is connected to a hydroxyl, with H1 (3.28 ppm) 
connected to the epoxide. 
 The HSQC data supported the assignment of the tertiary protons, while 
the HMBC data were used to unequivocally determine the assignment of the 
quaternary signals: The 60 ppm chemical shift for C1' supports the loss of 
aromaticity in the R' ring. Both C1 and C7 are sp3 hybridized and connected to 
oxygen, with chemical shifts of 70 and 71 pmm, respectively. The C2 to C6 bond 
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was determined from HMBC cross-peaks between C1 and C6, as well as cross-
peaks between C2 and C7. On the basis of the 103.5 ppm chemical shift for C4, 
and the singlet peak for H4 (4.9 ppm), we concluded that in the β-diketo moiety 
exists keto-enol configuration. C3 and C5 have chemical shifts of 205 and 206 
ppm, respectively. HMBC crosspeaks between each MeO peak and C3' or C3" 
allowed for their assignment the different rings. 
 The NMR data for 6a closely match that of 6b, with only minor variations 
in the chemical shifts. One noteworthy difference is the coupling constant (J) 
between H6 and H7, which is 2.7 Hz for 6a and 7.6 Hz for 6b.  
1H and 13C NMR chemical shifts and characteristic couplings are summarized 
in Table B6 (6a) and Table B7 (6b). 
 
Product 7a, vinylether-cyclopentadione 
 Product 7a was identified as a dioxygenated, vinyl-ether metabolite. 
Chromatographic separation was achieved using a RP-HPLC with pH 7.5 10 mM 
NH4OAc buffer. It was eluted at 16 min (Figure 2.7). Products 7a co-elutes with 
its diastereomer 7b, which was not sufficiently stable for NMR analysis. Both 
compounds were identical with respect to HPLC retention time, MS, MS-MS, and 
UV analyses. 
 ESI/HR/MS analysis of 7a in negative ion mode showed accurate 
molecular ion peak at m/z 399.1084, representing an increase of 32 amu 
compared with that of curcumin. Tandem MS studies showed the existence of 
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precursor ion ([M-H]-) at m/z = 399 and intense fragments at 247 (base ion), 355, 
313 and 151. 
 1H NMR spectra showed 10 proton and 2 MeO peaks. Six of the protons, 
at 6.9 - 6.3 ppm, belong to the phenolic moiety and suggested an aromatic 
conformation of both rings. The most downfield shifted proton was H1′ at 7.15 
ppm, and is connected to the C1=C2 double bond and an oxygen that forms the 
ether bond between C1 and C1'. The proton–proton cross-peaks observed in the 
COSY analysis supported the assignment of H6 and H7 as neighboring protons 
(J = 4.04 Hz), and H4 and H1 as isolated protons.  
 The HSQC supported the assignment of the tertiary protons, while the 
HMBC data was used to unequivocally determine the assignment of the 
quaternary signals; five signals in the HSQC between 145 and 150 ppm 
substantiated four sp2 quaternary carbon attached to oxygen atoms. C2 is a also 
a quaternary sp2 carbon, with chemical shift of 106 ppm. C7 is connected to 
oxygen, with chemical shift of 73.1 ppm. The C2 to C6 cyclization was 
determined from HMBC cross-peaks between C1 and C6, as well as cross-peaks 
between C2 and C7. On the basis of the 187.6 ppm and 210.1 ppm chemical 
shifts for the quaternary signals of C3 and C5, respectively, we concluded that 
the β-diketo moiety exists in a C5 keto, C3 enol conformation. Furthermore, C4 is 
a singlet at 109.4 ppm. HMBC crosspeaks between each MeO peaks and C3' or 
C3" allowed for their assignment to the different aromatic rings. 1H and 13C-NMR 
chemical shifts and characteristic couplings are summarized in Table B8. 
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Product 9, diguaiacol 
 Product 9 was identified as diguaiacol. It was eluted at 23 min (Figure 
2.7). ESI/MS analysis in negative mode of 9 showed m/z 245. MS2 analysis 
(product ions of m/z 245) yielded these major fragment ions: m/z 245 ([M-H]-), 
185, and 157. 
 1H NMR spectra showed 3 aromatic protons occurring between 6.5 and 
7.5 ppm, and 1 MeO peak at 1.8 ppm, representing half the symmetrical 
molecule. The HSQC data showed 3 peaks (for the 6 protons) in the 110 - 120 
ppm region of the spectrum, supporting our conclusion that these protons are 
attached to sp2 hybridized carbons. The HMBC data further corroborated the 
proton assignment as well of assignment of the quaternary signals. 
 
2.3.3 Mechanistic studies into curcumin oxidation 
Reaction progress: Identification of reaction intermediates 
 The identification of 6a and 6b as spiroepoxides prompted further study 
into their reaction since a similar structure was proposed as an intermediate to 
the bicyclopentadione. Furthermore we knew from handling the spiroepoxides 
that they were chemically unstable. 
 LC-MS analysis of isolated fractions of 6a and 6b in pH 7.5 buffer over 6 h 
is shown in Figure 2.9. 6a disappeared within the first 3 h to form 7a which then 
formed the bicyclopentadiones 8b and 8c (Figure 2.9B). The parallel reaction 
with 6b showed similar reaction, however, 6b reacted faster (than 6a) and 
disappeared within 1 h to form 7b. 7b persisted over the 3 h, with only small 
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amounts of transformation to 8a detected. Figures 2.9 C and D show the time 
course for formation of the bicyclopentadiones over a 6 h from by plotting the 
relative abundance of 6, 7 and 8 from ion chromatograms generated during the 
same experiment. Products 2-5 showed no reaction after further incubation for up 
to 12 hrs (data not shown). 
 
 
 
 
FIGURE 2.9 Conversion of the intermediates 6a (A) and 6b (B) to the 8 via 
intermediates 7a and 7b. Ion chromatograms were recorded every 15 min during a 6 hr 
incubation of 6a and 6b at room temperature. The products were monitored at m/z 399. 
(C and D) Time course of bicyclopentadione formation. The curves were obtained by 
fitting to the Gaussian distribution. 
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Analysis of oxygen incorporation into the bicyclopentadione 
 In a previous publication from our laboratory, Griesser et al. showed that 
only one of the two newly incoporated oxygen in the bicyclopentadione was from 
H2O, with the other coming from O2. (Griesser et al. 2011). It was proposed that 
the reaction with H2O occured with an early quinone methide intermediate, but 
this was never shown directly. The isolation of oxygenated reaction intermediates 
allowed us to re-examine the step in the reaction scheme at which the reaction 
with H2O occurs. I performed curcumin autoxidation in buffer made of 50% H218O 
and analyzed each product for the incorporation of the heavy atom using LC-ESI-
MS. As shown in Figure 2.10, only the vinylether 7 and bicyclopentadione 8 
contained 18O from H218O as evident from the 50% enrichment of the 401 (+2 
amu) ion. The spiroepoxide 6 and products 2-4 did not incorporate 18O, 
suggesting that the reaction with H2O occured during the transformation of 6 to 7. 
Neither 7 nor 8 exchanged 18O after incubations in H218O buffer. 
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FIGURE 2.10. Partial LC-ESI mass spectra of curcumin autoxidation products formed in 
a 1:1 mixture of H2O and H218O. 
 
Site of oxygen incorporation in the bicyclopentadione. 
 The proposed reaction mechanism in which H2O reacts with an early 
quinone methide intermediate positions the oxygen from H2O into the 
tetrahydrofuran ring between C1 and C7 of 8 (Griesser et al. 2011). While LC-MS 
studies supported that assignment of the oxygen, the data were not unequivocal. 
In re-examining these studies, I used more specific and sensitive LC-MS and 
NMR methods to determine which of the two newly incorporated oxygen atoms 
was from H2O and which was from O2. 
In the first of two approaches I sought to generate unambiguous 
fragmentation of 18O-8 formed in H218O to determine the part of the molecule that 
has the 18O label. CID of the unlabeled 8 (at m/z 399) and 18O-labeled 8 (m/z 
401) showed a base ion at m/z 247 or 249, respectively, suggesting that the 247 
fragment contained the heavy atom. Both spectra also shared fragments at m/z 
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151 and m/z 353 (Figure 2.11A & B). Since the 247/249 fragment could be 
reasonably generated in a manner to include either oxygen, we modified our 
approach to use an unsymmetrical analog of 8 (3’-OCD3,4”-Omethyl-8) to obtain 
unambiguous fragments (Figure 2.11 B). We generated 3’-OCD3,4”-Omethyl-8 
from autoxidation of the corresponding curcumin analog that has deuterium for 
hydrogen in the methoxy of one ring, and paramethoxy group at the second 
phenolic ring. CID of the [M-H]− molecular ions at m/z 416 and 418 (for the 18O-
product) showed a fragment ion at m/z 250 or 252, respectively, as the base 
peak (Figure 2.11C & D). These data suggest that the base peak fragments, 
bearing the d3- label, also have the labeled oxygen atom. Based on these results, 
the major fragment ions m/z 249 or m/z 252, contains the bicyclic ring moiety 
with one of the phenolic rings attached. Together, these data suggest that the 
18O derived from H218O formed the ether bond between carbons 1 and 1'. 
 
 
 
 
 
 
58 
 
 
 
FIGURE 2.11. LC-MS-MS spectra of 8 and 3’-OCD3,4”-Omethyl-8, respectively, formed 
in H2O or H218O. 
 
NMR Characterization of Oxygen-18-Labeled BCP analogs. 
To corroborate the LC-MS/MS data, I conducted 13C NMR analysis of 8 
generated in H218O or 18O2 that were then mixed in a 1:1 ratio with unlabeled 8 to 
observe the small upfield shift in the carbon signal connected to the heavy 
isotope (Baillie et al. 2001). When 8 was generated in 18O2:O2, the C-1 signal (at 
96.9 ppm) and C-7 signal (79.3 ppm) were shifted by 0.02 ppm indicating that 
both carbons were connected to the oxygen (in the tetrahydrofuran ring) derived 
from O2. (Figure. 2.12A). When 8 was generated in H218O:H2O, the C1 signal 
was shifted by 0.02 ppm but no shift was observed for C-7 (Figure. 2.12B) 
suggesting that the oxygen connecting C1 to C1’ in the phenolic ring was derived 
from H2O. We did not observe the expected shift of the C1’ signal. Nonetheless, 
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the data corroborate the previous the LC-MS/MS analysis and show that the 
oxygen from H2O is positioned between C1 and the aromatic ring (C1'). 
 
 
 
FIGURE 2.12. Partial 13C NMR spectra of 8 formed in a 1:1 mixture of (A) O2 and 18O2 
and (B) H2O and H218O showing the signals for C-1 and C-7 are shown. 
 
 
Analysis of the bicyclopentadione formed in D2O  
 The molecular structure of 7a shows a C1-C2 double bond that becomes 
saturated during the formation of 8. To confirm the existence and location of this 
double bond in 7, I conducted curcumin autoxidation in D2O buffer and assessed 
for the incorporation of deuterium into 8 by NMR. Partial 1H NMR spectra of 8 
formed in D2O buffer shows the incorporation of deuterium at C2, as indicated by 
the lack of a proton signal. The expected coupling of H2 into the neighboring H6 
carbon was also lacking, further confirming the incorporation of deuterium at C2 
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(Figure 2.13A & B). The 1H spectra for 8 and [D]-8 were otherwise identical. This 
data supports the existence of the C1-C2 double bond in 7. 
 
 
FIGURE 2.13 Partial 1H NMR spectra of the bicyclopentadione  formed in regular buffer 
(A)  and D2O buffer (B). 
 
Autoxidation of methylcurcumin 
 Curcumin autoxidation is initiated by hydrogen abstraction from either of 
the two phenolic hydroxyls in the symmetrical molecule. After hydrogen 
abstraction, the ring bearing the phenoxyl radical and eventual quinone methide 
will determine the position of the incorporated oxygen atoms in the final product 
8. To determine whether the ether bond at C1 in 8 will connect the ring that has 
the additional methyl group, or the other ring where H-abstraction is permitted 
and therefore contained quinone methide and phenoxyl radical. I performed 
oxidation of methylcurcumin (using the oxidant K3[FeCN)6]) to generate the 
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corresponding methyl-8. Methylcurcumin does not undergo autoxidation. NMR 
analysis showed that the methyl group was found exclusively in the ring 
connected to C7 rather than the ring connected through the ether bond at C1 
(Figure 2.14). This places the ether bond on the side of the molecule where the 
H-abstraction occurred to form the quinone methide. The implications of this 
finding is further discussed in the next section. Partial NMR spectra from the 
identification of methyl-8 are shown in Figure B1 of the Appendix. 
 
 
 
 
2.3.4 Curcumin metabolism in human S9 liver fractions.  
 We have shown that curcumin is a substrate for horseradish peroxidase 
(HRP) and COX-2 at the peroxidase active site, resulting in formation of the 
bicyclopentadione products (Griesser et al. 2011). Similar oxidation to generate 
quinone methides in other polyphenols is catalyzed by both peroxidases and 
cytochrome P450 enzymes (Mahajan et al. 2011). Implicating the involvement of 
P450 enzymes in the catalysis of curcumin would suggest enzymatic 
transformation in the liver could contribute to the formation of the oxidized 
metabolites in vivo. 
FIGURE 2.14  Oxidation of methylcurcumin.  
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 Human S9 liver fractions were used as a model to determine the 
contribution of liver metabolism in the oxidative transformation of curcumin in 
vivo. Experiments were performed using [14C2]curcumin as a tracer in order to 
account for potential novel, enzyme specific metabolites. Reactions were 
conducted in the presence (Figure 2.15B) or absence (Figure 2.15A) of NADPH. 
 NADPH  dependent transformation of curcumin to the reduced 
hexahydrocurcumin product (identified by comparison to an authentic standard) 
was the only reaction detected. None of the oxidized products were detected.  
 
 
 
 
 
 
 
 
 
 This study indicates that the P450 enzymes in the liver may not be 
involved in the oxidation transformation of curcumin in vivo. Nonetheless, it is 
possible that peroxidase enzymes in other tissues may contribute to the 
FIGURE 2.15. Radio-chromatogram showing reaction of [14C2]curcumin with S9 liver
fractions. 25 M [14C2]curcumin is incubated with 500 L 0.1 M KPO4  buffer pH 7.4,
2.5 mg S9 protein, 3 mM MgCl2, with or without 2 mM NADPH for 30 min. The
reaction was terminated by the addition of 1 mL MeCN, and the supernatant dried
and reconstituted for HPLC-radio analysis.  
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enzymatic formation of the oxidative metabolites. Many target tissues express 
peroxidase enzymes that are involved in oxidation activation of drugs to reactive 
metabolites in vivo, e.g., myloperoxidase (in leukocytes), P450 peroxidase, and 
the COX enzymes (expressed in multiple tissues) (O’Brien 1988; Stiborová et al. 
2007). The relative contribution of enzymatic versus autoxidative transformation 
in the in vivo oxidation of curcumin has not been assessed. 
 
2.4 Discussion 
 
Mechanism of curcumin oxidation: 
 The isolation and structural identification of novel products and reaction 
intermediates, in conjunction with mechanistic studies using isotopic and 
structural analogs of curcumin (2H-) or its metabolites (2H- and 18O-), allowed us 
to determine a mechanism of autoxidation (Figure 2.16). The reaction is initiated 
by hydrogen abstraction from either of the phenolic hydroxyls to form a phenoxyl 
radical. This radical is delocalized to a more stable carbon-centered position at 
C2 in the heptadieneone chain, also forming a quinone methide in the process. 
The secondary radical at C2 undergoes 5-exo cyclization reaction to form the 
cyclopentadione ring of C2 to C6. The resulting radical at C7 either reacts with O2 
to form a peroxyl radical (preferred reaction route) (Figure 2.16), or participates in 
a second cyclization reaction with the sp2 carbon at C1 to form 5, a minor 
reaction product (Figure 2.18). In the case of the reaction with O2, the resulting 
peroxyl radical III also reacts with the sp2 carbon at C1 to from an endoperoxide 
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with a tertiary radical at C1' IV. The endoperoxide radical undergoes two 
alternative reactions: The radical is quenched by H-donation to form a covalently 
complete endoperoxide VI that we propose is the precursor to 2, 3 and 4 (Figure 
2.17). Alternatively, the radical performs SHi attack at the endoperoxide to form a 
spiroepoxide and alkoxyl radical V that is quenched to form the covalently 
complete 6. Product 6 undergoes ring opening of the epoxide by C-C bond 
cleavage along with exchange of oxygen to form vinylether 7. Addition of the 
hydroxyl of 7 across the C1-C2 double bond completes the formation of 8 as the 
major autoxidation product. Product 9 is presumably formed from the alkoxyl 
radical that can also undergo homolytic -scission of the C1-C1' bond to release 
a methoxy phenol radical that dimerizes to give the final product (Figure 2.19). 
The formation of diguaiacol from curcumin autoxidation is unexpected, and our 
proposed mechanism is likely an oversimplification of a more complex 
mechanism. The dimerization of the methoxyphenol radical, which likely exists at 
very low concentrations, is puzzling. 
18O-labeling studies showed that 8 retains one of the oxygen initially 
incorporated from O2, and has a second oxygen incorporated from H2O. The 
oxygen from H2O forms the ether bridge between C1 and C1' in the phenolic ring 
in 8 and, we presume, the similar ether bridge in 7. This implicates that the 
exchange of oxygen occurs in conjunction with the epoxide opening in 6 during 
the formation of 7. The opening of an epoxide in this manner to involve an 
oxygen exchange is unprecedented in the literature. 
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 Our analysis further shows differential reaction rates for the transformation 
of the diastereomers of 6 and 7 during the formation of 8. No scrambling of the 
stereoisomers occurred during this reaction, with 6a going to form 8b, c via 7a, 
and 6b going to 8a through 7b, suggesting that no racemization occurred during  
this transformation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.16 Proposed mechanism  
of autoxidation of curcumin. 
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FIGURE 2.17 Proposed mechanism of formation of 2, 3 and 4. 
 
 
 
 
 
 
FIGURE 2.18 Proposed mechanism of formation of 5. 
 
 
 
 
 
 
FIGURE 2.19 Proposed mechanism of formation of 9. 
 
 
 
 
HO
H3CO
OH
HO O
HO OH
OCH3
O
OHO
OH
OHO
OCH3
HO
OO
OH
OHOOCH3
O
OO
OH
OHO
+ H
IV V
2
3 4
HO O
O
HO OH
OCH3H3CO
OH
OCH3
red.
H3CO H3CO
H3CO
OCH3
OHHO
H3CO
OH
OCH3
O
H3CO
OH
HO O
OCH3
OO
V
9
C14H12O6
2
5 6
 
 
67 
 
Comparisons with the old mechanism 
In the previously proposed mechanism of curcumin autoxidation, the 
secondary radical formed after migration of the phenoxyl radical also reacts with 
O2, but the resulting peroxyl radical is quenched to form a hydroperoxide 
intermediate. The quinone methide is quenched by reaction with water (at C1) to 
account for the incorporation of oxygen from H2O into the bicyclopentadione. 
Furthermore, the proposed spiroepoxide was formed from the hydroperoxide and 
placed across the C7 and C1” bond.  
Our 18O-labeling studies proved that the reaction with water does not 
occur at the quinone-methide, but at a later step in the reaction during the 
formation of 7 from 6. Furthermore, the identification of the hemiketal and 
dihydroxy products points to the existence of an endoperoxide intermediate, 
supporting a reaction of the peroxyl radical with the quinone-methide, and argues 
against a hydroperoxide intermediate. Even though the spiroepoxide 
intermediate was proposed during the earlier mechanism, the epoxide was 
placed across C7 and C1’'. The oxidation of methylcurcumin suggest that the 
epoxide exists across the C1 and C1’ bond that formed part of the quinone-
methide (Figure 2.20). Furthermore, our 18O-labeleled studies of 8 showed that 
the oxygen atom from water formed the ether bond between C1 and C1’, rather 
than being part of the tetrahydrofuran ring as previously proposed.  
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FIGURE 2.20 Proposed mechanism of oxidation of methylcurcumin. 
 
Oxygen Exchange 
 The transformation mechanism elucidated for curcumin to incorporate 
oxygen from H2O and O2 is complex and is unprecedented in the oxidation of 
phenolic compounds. Individual steps during the transformation represent 
complex reactions and perhaps unprecedented chemistries as well. The most 
puzzling step of the reaction is the exchange of oxygen that occurs during the 
transformation of the 6 to 7. Our data suggests that the exchange of oxygen 
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occurs in conjunction with the carbon-carbon bond cleavage during opening of 
the epoxide of 6, rather than at QM as previously proposed. Suggesting a 
chemical mechanism to support this transformation proved non-trivial. In control 
experiments, no exchange of oxygen was detected after incubations of purified 6 
and 7 in 18O-labeled buffer, suggesting chemical reaction with water occurs 
during the transformation. The details of this transformation therefore remain to 
be explained.  
 
The oxidative products are nucleophilic -dicarbonyls  
The extreme polarity of oxidative products 2-5, as evident from their early 
elution time relative to 7 and 8, is unusual given their very similar chemical 
features. Products 2-5 also share a common UV chromophore with prominent 
maximum absorbance at 263 - 265 nm, which is different than that of 7 and 8 
(Figure 2.21A). The differences in polarity and UV chromophore can both be 
attributed to differences in the nucleophilicity of the -diketone moiety that acts 
as a carboxylic acid isostere. Products 2-5 exist as ionic species at pH 7.4 and 
are deprotonated at the central C4 position in the -diketone moiety. 1H NMR 
experiments suggest that the proton at C4 quickly exchanges for deuterium in 2-
5. Protonation at C4 results in a reversible change in the chromophore of 2 to 
match that of 8 (Figure 2.21B). The nature of the substituent at C1 and C7 seems 
to affect the acidity at C4.  
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FIGURE 2.21  (A) UV/Vis spectra of 6, 7 and 8. (B) UV/Vis spectra of 2a at pH 3.4, 4 
and 8. 
  
Curcumin quinone methide poisons topoisomerase II 
 The analysis of the oxidative metabolites presented in this chapter is an 
initial step towards assessing their involvement in the bioactivities of curcumin. 
The first study to suggest a role for oxidative metabolism in the biological effects 
of curcumin was a collaborative effort between our laboratory and that of Dr. 
Osheroff. Our studies implicate the proposed quinone methide as the direct 
mediator of the topoisomerase poisoning effect of curcumin. 
Curcumin can induce apoptosis in cancer cells and its effect on the 
topoisomerase enzymes is considered an important contributor (Pawar et al. 
2012; López-Lázaro et al. 2007; Ketron et al. 2013). Topoisomerases regulate 
DNA integrity during replication by cutting and religating DNA strands to relieve 
tangles and supercoils. The two major classes of topoisomerases, type I and 
type II, act by forming a transient single or double-strand break, respectively. In 
the case of the type II topoisomerases, a covalent “cleavage complex” 
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intermediate is formed between an active site tyrosine residues and newly 
generated DNA termini (Wang 1996; Nitiss 1998). Several anti-cancer agents 
such as etoposide and doxorubicin act by stabilizing this cleavage complex, 
leading to eventual DNA strand breaks and apoptotic cell death. Drugs that act in 
this manner are referred to as topoisomerase poisons (Bender, Ham, and 
Osheroff 2007; Deweese and Osheroff 2009). Quinones form a class of 
topoisomerase poisons, and bind covalently to Cys-392 and Cys-405 in 
topoisomerase II to increases levels of cleavage complexes primarily by inhibiting 
DNA religation (Bender, Ham, and Osheroff 2007). Quinones exhibits both 
antitumor and carcinogenic activities (H. Wang et al. 2001). 
Curcumin is a potent topoisomerase II poison in cells, showing greater 
activity than etoposide and other clinically used drugs that target that enzyme 
(López-Lázaro et al. 2007). In our study, we assessed the mechanism of action 
of curcumin against topoisomerase II in vitro. The assay used a purified 
recombinant enzyme and plasmid DNA. DNA cleavage was measured to indicate 
poisoning of the enzyme. Curcumin displayed no activity in this system when 
tested at 10 to 150 M. In investigating the role of oxidative metabolism, we 
showed that curcumin is stable to autoxidation in the assay buffer due to the 
presence of MgCl2 and antioxidants, and none of the oxidative products were 
formed (Figure 2.23A). Inducing oxidative transformation with stoichiometric 
concentrations of oxidizing agent potassium ferricyanide (K3Fe(CN)6) resulted in 
potent topoisomerase II poison activity, suggesting that oxidative transformation 
is required for this effect (Figure 2.23B). Stable curcumin analog 
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dimethylcurcumin did not induce DNA cleavage even after the addition of the 
K3Fe(CN)6 oxidant.  
 
 
 
 
 
 
 
 
 
 
 
  
To support a redox-depended, covalent binding mechanism of action of 
curcumin, we showed that the addition of antioxidant DTT prior to the addition of 
the enzyme results in loss of the curcumin effect, presumably by preventing the 
covalent association of electrophile metabolite(s) of curcumin with the enzyme. 
The spiroepoxide 6, which exhibits electrophilic properties in reactions with GSH 
50 M K3Fe(CN)6
added at 10 min 
Topoisomerase assay buffer (pH 7.9)
2.0
0
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FIGURE 2.22 Topoisomerase-II poisoning effect of curcumin.  (Left) Curcumin
is stable in the assay buffer over 10 minutes after repetitive scanning in the
spectrophotometer every 1 min. Addition of K3Fe(CN)6 induces oxidative
degradation of curcumin. (Right) Curcumin shows no DNA  cleavage when
K3Fe(CN)6 is absent. Addition of K3Fe(CN)6  results in 4 fold increase in DNA
cleavage (Ketron et al. 2012). 
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(Figure 4.4), was only 50% as potent in the topoisomerase poisoning assay 
compared to when curcumin is used. Neither the bicyclopentadione 8 nor a 
mixture of products 2 - 5 showed appreciable effect on topoisomerase. When 
curcumin is pre-incubated with topoisomerase and K3Fe(CN)6  prior to the addition 
of the DNA, the enzyme activity decreased to about zero with a half-life of 0.9 
min, consistent with the prediction for redox-dependent poisons. These studies 
implicate the early quinone methide intermediate as the direct mediator of the 
topoisomerase effect of curcumin. This is the first instance where a curcumin 
target can be attributed to one of the oxidative metabolites (Ketron et al. 2013). 
Establishing the involvement of the quinone methide in the topoisomerase 
effect of curcumin is an elegant explanation for the discrepancy between the in 
vitro and cellular data. Cells may possess the enzymatic machinery to oxidize 
curcumin, and this is lacking in the cell-free system. Our studies can serve as a 
model for assessing the involvement of the quinone methide against other 
curcumin targets. 
 
Conclusions 
 The rapid degradation of curcumin at physiological pH has been 
recognized for many years, but the major products remained unidentified. A 
recent study by our group identified the degradation of curcumin as an 
autoxidation and the final product as a dioxygenated bicyclopentadione 8. The 
discovery of 8 as the major product of curcumin degradation in buffer corrects 
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earlier literature reports stating that curcumin degradation in buffer is mainly a 
chain cleavage reaction generating vanillin and ferulic acid (Wang et al. 1997).  
In the present study, I have isolated ten additional products of this 
transformation, including four reaction intermediates. We have refined and 
expanded on our previously proposed mechanism to include transformation 
through a proposed endoperoxide intermediate that proceeds through the 
isolated spiroepoxide 6 and vinylether 7 intermediates to form 8. I have 
determined conditions for the isolation of the oxidative metabolites to allow for 
their evaluation in biological assays. We hypothesize that the oxidative 
metabolism of curcumin contributes to its therapeutic effects. This study 
represents the first example of the isolation and structural characterization of 
reactive intermediates formed during oxidative transformation of a natural 
polyphenolic agent of high medicinal interest. 
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CHAPTER 3 
 
MECHANISTIC STUDIES INTO THE OXIDATIVE TRANSFORMATION OF 
CURCUMIN-GLUCURONIDE 
 
3.1 Introduction 
3.1.1 Curcumin glucuronidation 
Glucuronidation is the most common route for the phase II metabolism of 
curcumin. Conjugation of curcumin with the glucuronic acid occurs in the liver 
and intestines. UDP-glucuronosyltransferases (UGTs) are a family of enzymes 
responsible for converting curcumin to the more polar conjugate through the 
nucleophilic addition of the glucuronic acid moiety (Ritter 2000). The O-
glucuronide, in which the glucuronide is attached at one of the phenolic 
hydroxyls, is the abundant conjugation product of curcumin in vivo and has been 
found at much higher concentrations than the unconjugated curcumin (Pan, 
Huang, and Lin 1999). The comparatively high levels of curcumin-glucuronide in 
the plasma raise the question of its contribution to the pharmacological effects of 
curcumin. In rare cases, glucuronides of other drugs have been shown to have 
increased biological activity, or serve as a transporter form for the parent 
compound (Pasternak et al. 1987). The contribution of the curcumin-glucuronide 
to the biological activity of curcumin is unclear. 
  Autoxidative transformation is the major pathway for the in vitro 
degradation of curcumin, giving rise to dioxygenated derivatives. Oxidation of 
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curcumin involved hydrogen abstraction from either of its phenolic hydroxyls. The 
glucuronide conjugate of curcumin still has one free hydroxyl. We know from 
previous analysis of methylcurcumin that only one free hydroxyl is required for 
oxidative transformation to occur. However, blockage of the second hydroxyl 
group prevents autoxidation, and oxidative transformation then requires the 
action of peroxidase enzyme (e.g. HRP) or oxidant (e.g. K3Fe(CN)6). The 
chemical instability of the phenolic curcumin-glucuronide in aqueous buffer at pH 
7.4 has been reported, but the products and reaction mechanism were not 
determined (Pfeiffer et al. 2006). The aims of the studies in this section were to 
investigate the oxidative transformation of curcumin glucuronide, and determine 
the reaction products. 
 
3.2 Materials and Methods 
 
3.2.1 Materials 
 Curcumin was synthesized from vanillin and acetylacetone as described. 
HRP (Type-II, 5 kU/ml; 25.9 mg/ml) was purchased from Sigma (P8250).  
 
3.2.2 Synthesis of curcumin glucuronide 
Curcumin glucuronide was synthesized following a protocol by Moon et al. 
(Moon et al. 2001). Curcumin (100 mg, 0.27 mmol) and acetobromo-α-D-
glucuronic acid methyl ester (500 mg, 1.26 mmol) were dissolved in 5 ml 
dimethylformamide. K2CO3 (100 mg, 0.72 mmol) was added, and the solution 
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was stirred for 2 h at room temperature. Then 30 ml cooled H2O were added and 
the solution was acidified using formic acid. Acidification resulted in the formation 
of a precipitate that was collected by centrifugation (4°C, 5000 rpm, 20 min). The 
precipitate was washed with 5 ml 0.2% formic acid and dissolved in 10 ml 50/50 
MeOH/CHCl3. The solvent was evaporated and the residue was dissolved in 5 ml 
dry MeOH. In order to remove the acetyl moieties 150 μl NaOH (28% in MeOH) 
were added, and the solution was stirred for 30 min at 4°C. The methyl ester was 
hydrolyzed by treatment with 5 ml H2O for 30 min at room temperature. Then 
370 μl HCl (2.0 N) and a few drops of formic acid were added to acidy the 
solution. The solution was filtered, and the solvent evaporated. The product was 
purified by RP-HPLC (Econosil C18 column, 250 mm x 10 mm) eluted with a 
solvent of MeCN/H2O (45/55) with 0.01% acetic acid at a flow rate of 4 ml/min. 
LC-MS: 543 ([M − H]−).1H NMR (Acetone-d6, 600 MHz): δ = 7.60 (d, 1H, J = 15.8), 
7.59 (d, 1H, J = 15.7 Hz), 7.35 (d, 1H, J = 1.14 Hz), 7.33 (d, 1H, J = 1.7 Hz), 7.21 
(m, 1H), 7.20 (m, 1H), 7.18 (dd, 1H, J = 8.2; 1.8 Hz) 6.87 (d, 1H, J = 8.2 Hz), 6.76 
(d, 1H, J = 15.8 Hz), 7.71 (d, 1H, J = 15.8 Hz), 5.99 (s, 1H), 5.20 (d, 1H, 
J = 7.39 Hz), 4.10 (d, 1H, J = 9.8 Hz), 3.91 (s, 3H), 3.88 (s, 3H) ppm. 
 
3.2.3 Analytical procedures for synthesized compounds 
Products were analyzed and purified by RP-HPLC using an Agilent 1200 
series diode array system equipped with a Waters Symmetry C18 5-µm column 
(4.6 × 250 mm). The column was eluted with a linear gradient of 
MeCN/H2O/HOAc 20/80/0.01 to 80/20/0.01 (by vol.) over 20 min and a flow rate 
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of 1 ml/min (Method A). LC-MS was performed using a Thermo LTQ ion trap 
instrument equipped with an electrospray ionization interface. The instrument 
was operated in the negative ion mode, and mass spectra were acquired at a 
rate of 2 s/scan. The settings for the heated capillary (300 °C), spray voltage 
(4.0 kV), spray current (0.22 μA), auxiliary (37 mTorr), and sheath gas (16 mTorr).  
Samples were introduced using a Waters Symmetry Shield C18 3.5-µm column 
(2.1 × 100 mm) eluted with a gradient of MeCN/H2O (5/95, by volume, containing 
.05% acetic acid) to MeCN/H2O (95/5, by volume, containing .05% acetic acid) 
over 10 min.  Curcumin glucuronide was identified based on comparison with an 
authentic commercial standard. 
 
3.2.4 Oxidation of curcumin glucuronide 
Curcumin glucuronide or curcumin (30 μM) were added to 500 μl 20 mM 
Na-phosphate buffer pH 7.5. The reaction was monitored in a UV/Vis 
spectrophotometer by repetitive scanning from 700 to 200 nm every 2 min or by 
following the disappearance of the chromophore at 430 nm in the time drive 
mode. To some reactions K3Fe(CN)6 (15 μM; from a 5 mM stock solution in 
water) or horseradish peroxidase (0.01 U/ml) and H2O2 (40 μM) were added.  
A large scale incubation of curcumin glucuronide (1 mg) with 50 μM K3Fe(CN)6 
was conducted in 40 ml of buffer for 20 minutes. Products were extracted after 
acidification on C18 cartridge eluted with methanol. 
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HPLC Analysis 
The transformation reactions were analyzed using a Waters Symmetry 
C18 5-μm column (4.6 × 250 mm) eluted with a gradient of 20% MeCN to 80% 
MeCN in 0.05% aqueous acetic acid over 20 min. The samples run at flow rate of 
1 ml/min. Elution of the products was monitored using an Agilent 1200 diode 
array detector. 
 
LC-MS Analysis 
For LC-MS analyses a Thermo Finnigan LTQ ion trap instrument. The 
settings for the heated capillary (300 °C), spray voltage (4.0 kV), spray current 
(0.22 μA), auxiliary (37 mTorr) and sheath gas (16 mTorr). Samples were 
introduced into the instrument using a Waters Symmetry Shield C18 3.5-μm 
column (2.1 × 100 mm) eluted with a gradient of 20% acetonitrile to 80% MeCN 
in 0.05% aqueous acetic acid over 5 min, followed by isocratic elution with 95% 
MeCN for 5 min. 
 
NMR Analysis 
Samples were dissolved in 150 μl of acetone –d6 in a 3 mm tube, and the 
NMR spectra were recorded using a Bruker DRX 600 MHz spectrometer 
equipped with a cryoprobe. The pulse frequencies for the H,H-COSY, HSQC, 
and HMBC experiments were taken from the Bruker library. The spectra were 
acquired at 284 K. Chemical shifts are reported relative to residual acetone (δ = 
2.05 ppm).  
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3.3 Results 
 
3.3.1 Oxidation of curcumin-glucuronide 
 Following up on the transformation of curcumin in buffer, the reaction of 
curcumin-glucuronide was assessed under similar conditions. Spectro-
photometric analysis shows that curcumin-glucuronide was stable to autoxidation 
in phosphate buffer pH 7.5 (not shown). The addition of HRP to the buffer 
resulted in little degradation over a 10 min time course with the further addition of 
the H2O2 catalyst resulting in the fast disappearance of the curcumin-glucuronide 
chromophore at λmax 430 nm (Figure 3.1).  
 
 
 
The addition of a half-stoichiometric amount of the oxidizing agent potassium 
ferricyanide (K3Fe(CN)6) also catalyzed this transformation. The disappearance 
of the 420 nm chromophore was associated with the formation of a new 
chromophore at 263 nm, matching that seen during curcumin oxidation and 
suggesting the same type of transformation. 
FIGURE 3.1  UV/VIS analysis of 30 M 
curcumin-glucuronide oxidation in 500 μl 
20 mM Na-phosphate buffer pH 7.5. The 
reaction is scanned repetitively from 700-
200 for 5 min in the presence of HRP 
before H2O2 is added for 3 min. Scan 
rate: 1 min-1.
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 I conducted kinetic analysis in a spectrophotometer to compare the rate of 
autoxidative, K3Fe(CN)6 catalyzed, and HRP/H2O2-catalyzed transformations of 
curcumin and curcumin-glucuronide in pH 7.5 buffer. The assay measured the 
change in the absorbance of curcumin (430 nm) or curcumin glucuronide (420 
nm) over the first 45 sec upon the addition of the enzyme or oxidant. The 
obtained values are the average of three repeats performed for each experiment. 
 
TABLE 3.1 Kinetic analyses of the oxidation of curcumin and curcumin-glucuronide. 
 
 As shown in Table 3.1, curcumin-glucuronide was practically stable under 
autoxidative conditions when compared to curcumin. Curcumin-glucuronide 
transformation was about 80% as fast with the enzyme (HRP/H2O2) and about 
50% as fast with the oxidant (K3Fe(CN)6) compared to curcumin. Curcumin-
glucuronide was therefore an efficient substrate for the oxidant and enzyme, 
howbeit not as efficient as curcumin.  
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3.3.2 HPLC and LC-MS analyses of curcumin-glucuronide oxidation. 
Curcumin-glucuronide oxidation reactions were conducted using 
HRP/H2O2. The reactions were acidified and the products separated on RP-
HPLC system with diode-array detection. The chromatogram, presented in 
Figure 3.2A, shows two polar products eluting at 7 and 7.5 min retention time 
with the same UV/Vis spectra as the curcumin bicyclopentadiones. A similar 
reaction conducted in parallel was treated with β-glucuronidase in order to 
remove the glucuronic acid moiety from the products and starting material. After 
hydrolysis, the two products were shifted to the same retention time as the 
bicyclopentadione isomers formed by autoxidation of curcumin (Figure. 3.2B and 
C). LC-ESI/MS analysis in negative ion mode of the major reaction product in 
Figure 3.2A shows m/z 575 representing an increase in 32 (2O) above the 
molecular weight of curcumin-glucuronide (m/z 543). These data suggest that the 
major product of curcumin-glucuronide oxidation is the bicyclopentadione-
glucuronide. Products from K3Fe(CN)6 and peroxidase-catalyzed reactions were 
identical based on RP-HPLC-UV and LC-MS/MS analysis. 
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FIGURE 3.2 RP-HPLC analysis of enzymatic transformation products of curcumin 
glucuronide. (A) 30 M Curcumin glucuronide was reacted with HRP and H2O2 (40 μM). 
(B) A reaction conducted in parallel in analyzed after hydrolysis with β-glucuronidase 
(pH4, 1 h at 37°C). (C) Transformation products of curcumin by HRP/H2O2) 
 
3.3.3 Characterization of the bicyclopentadione-glucuronide by NMR. 
 
 
 
 
FIGURE 3.3 Biclyclopentadione-glucuronide. 
The arrow shows the 3-bond 1H to 13C HMBC 
cross peak. 
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 To confirm the identification of the 
bicyclopentadione-glucuronide, and to 
determine which of the phenolic rings 
has the glucuronide moiety, NMR 
analysis was conducted on the major 
reaction product in Figure 3.3A after a 
large scale reaction.  
 1H NMR spectra closely matched 
that of the curcumin derived 
bicyclopentadione. Signals for the 
aromatic hydrogens H5’ and H6’ were 
shifted by 0.44 and 0.15 ppm, respectively, relative to those of the free 
bicyclopentadione indicating that the glucuronic acid moiety is attached to that 
ring. We detected HMBC cross peak between a glucuronic acid carbon and C4” 
as shown in Figure 3.3. 
 
3.4 Discussion 
 
 Oxidative transformation of curcumin-glucuronide in our study required the 
addition of HRP/H2O2 or the oxidizing agent K3Fe(CN)6. The rate of catalysis was 
TABLE 3.2 Proton chemical shifts of the
aromatic signals of the bicyclopentadione
(BCP) and bicyclopentadione glucuronide
(BCP-Glucu) 
δ1H (ppm)
No. BCP BCP‐glucu
1′ −
2′ 6.85 6.84
3′ − −
4′ − −
5′ 6.84 6.82
6′ 6.66 6.65
3′‐OMe 3.87 3.85
1″ −
2″ 6.74 6.88
3″ − −
4″ − −
5″ 6.69 7.13
6″ 6.71 6.86
3″‐OMe 3.76 3.79
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about 80% that of curcumin for the enzyme, and 50% for the oxidant. Using LC-
MS and NMR studies, the major products of the HRP and K3Fe(CN)6 mediated 
transformations were identified as the glucuronidated analog of the 
bicyclopentadione isomers. These studies imply that curcumin glucuronide can 
undergo the same oxidative transformation described for curcumin (Figure 3.4), 
and that curcumin-glucuronide could be subjected to further metabolism by 
peroxidase enzymes in vivo. The products of curcumin-glucuronide oxidation 
could contribute to the biological activities of curcumin. 
 The study by Pfeiffer et al found rapid degradtion of curcumin-glucuronide 
in pH 7.5 phosphate buffer at 37 ºC at rates higher than that of curcumin (Pfeiffer 
et al. 2006). In contrast, we found that the curcumin-glucuronide showed virtually 
no reactivity in ammonium acetate buffer at the same pH 7.5 at room 
temperature, compared to the rapid degradation of curcumin in the same system. 
It is not clear what accounts for the differences seen in these studies, even 
though the higher temperature (37 ºC) employed the first study is expected to 
increase the reaction rates overall. 
 The inhibitory effect of the glucuronic acid substituent on the autoxidation 
of curcumin is similar to what was observed for methylcurcumin; blocking one of 
the phenolic hydroxyls resulted in marked decrease in the autoxidation rate but 
still allowed for chemical and peroxidase-catalyzed oxidation. The steps following 
the initial hydrogen abstraction, including radical cyclization, oxygenation, and 
exchange of water to form bicyclopentadiones, are presumed to occur without 
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further interference from the glucuronide. The glucuronic acid moiety was 
attached to the hydroxyl of the R" ring in the bicyclopentadione.  
 
 
FIGURE 3.4 Oxidative transformation of curcumin and curcumin-glucuronide. 
 
Curcumin-glucuronide as a metabolism dependent pro-drug 
 Our data suggests that curcumin-glucuronide is not an inert phase II 
metabolite of curcumin but can be further oxygenated by peroxidase enzymes to 
generate potentially bioactive products. There are other exceptions to the notion 
that glucuronidation is solely a detoxifying mechanism. This long-accepted view 
changed with the discovery that morphine 6-glucuronide was up to 20 fold more 
potent than morphine (Pasternak et al. 1987) Subsequently, glucuronides were 
found to represent pharmacologically active forms of other drugs such as the 
Curcumin
Oxidative metabolites
Autox.
HRP
Curcumin-glucuronide
Autox
HRP
 
 
87 
 
serotonin 5-HT2A-receptor antagonist sarpogrelate, or the CYP2C8 inhibitor 
gemfibrozil (Kim et al. 2013; Ogilvie et al. 2006). Gemfibrozil is a presumed 
metabolism-dependent inhibitor of its target, requiring further transformation to 
reactive aldehydes that adduct to the protein.  
 We hypothesize that curcumin glucuronide can exhibit metabolism-
dependent activity, requiring oxidative activation to reactive products. Even 
though glucuronides are typically too hydrophilic to penetrate the cells, the 
unusual lipophilicity of curcumin-glucuronide has been reported, which could 
allow for its distribution into different organs (Pfeiffer et al. 2006). In fact, 
morphine 6-glucuronide shows high penetration into the brain despite its high 
polarity and low blood brain barrier permeability, possibly due to the involvement 
of active transport systems (Sattari, Routledge, and Mashayekhi 2011).  
 Glucuronidation may also contribute to the biological activities of curcumin 
by serving as a storage mechanism. The glucuronide conjugate of curcumin is 
more stable to autoxidation, and could be less susceptible to further metabolism, 
allow for 'intact' transportation to the sites as action where hydrolysis occurs. The 
notion that glucuronide conjugates may represents a 'transporter form' of a drug 
is well established, and has been exploited to deliver drugs directly to the site of 
cancers, e.g. doxorubicin (Weyel et al. 2000). 
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CHAPTER 4 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 The oxidative transformation of curcumin to a dioxygenated 
bicyclopentadione is a recent discovery in our laboratory. We hypothesize that 
the products of this transformation are direct mediators of some of the many 
bioactivities of curcumin. My approach in testing this hypothesis has been (1) to 
isolate and identify the oxidative products from in vitro model reactions, and (2),  
to elucidate the mechanism of formation of the isolated products.  
 I have successfully isolated ten novel products of this transformation, 
including four reaction intermediates, and have completed their structural 
identification using HPLC-UV, LC-MS, and a combination of 1D and 2D NMR 
methods. Mechanistic studies on the incorporation of 2H and 18O into the 
oxidative metabolites during reactions with 2H2O, H218O, and 18O2, enabled us to 
determine the mechanism of oxidative transformation of curcumin. The reaction 
is initiated by H-abstraction from either of the phenolic hydroxyls. The resulting 
phenoxyl radical migrates into the heptadienedione chain to form a quinone 
methide and carbon centered radical at C2. The radical participates in 5-exo 
cyclization to form a cyclopentadione ring of C-2 to C6. Oxygen addition to the 
resulting radical (at C-7) forms a peroxyl radical and subsequently an 
endoperoxide, followed by SHi carbon radical attack on the endoperoxide to form 
a spiroepoxide. The spiroepoxide 6 undergoes water exchange during 
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transformation to a vinylether 7 that is an immediate precursor to the final 
bicyclopentadione 8 (Figure 2.16). The phenolic glucuronide of curcumin 
undergoes enzymatic oxidative transformation to generate the 
bicyclopentadione-glucuronide, suggesting the same reaction mechanism as 
curcumin. The curcumin quinone methide is implicated as the direct mediator of 
the topoisomerase-poisoning effect of curcumin, supporting our hypothesis of the 
oxidative metabolites as contributors to the bioactivities of curcumin.  
 Establishing the in vivo formation of the oxidative metabolites of curcumin 
(and of that of its glucuronide conjugate) is an important part in supporting a role 
for oxidative metabolism in the biological activities of curcumin. We have 
developed stable isotope dilution mass spectrometry (MS) methods to detect and 
quantify curcumin, curcumin glucuronide, and their respective bicyclopentadione 
products in plasma. We have synthesized d6-labeled standards to be used in the 
quantification. Preliminary data by our group shows that the final 
bicyclopentadione product of curcumin oxidation is found in human and mouse 
plasma after oral dosage of curcumin. 
 Future pharmacokinetic studies in the laboratory will help determine the 
rate and extent of the formation of the oxidative metabolites in human subjects 
and in mice. Mouse studies will allow for tissue distribution to be evaluated by 
harvesting organs after administration of [14C2]curcumin tracer. The formation of 
reactive intermediates during the oxidation transformation of curcumin should be 
an important consideration in these studies, as adduction to biomolecules is 
expected to limit the amount of free compound that can be detected in the 
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tissues. The amounts of the free metabolites detected therefore are likely to be a 
partial reflection of the extent of oxidative transformation in vivo. Further, it may 
be that failure to find abundant levels of these metabolites, or at all, does not 
preclude their formation, especially at the sites of action.  Exploring contribution 
of peroxidase enzymes versus autoxidative transformation to the formation of the 
oxidative metabolites is also an interesting avenue of study. 
 
Are the oxidative metabolites biologically active? 
Curcumin modulates more than 100 cellular targets, and many of these 
are presumed to be through direct interaction. The antioxidant and electrophilic 
properties of curcumin primarily are implicated in its ability to modulate signaling 
in cells. As an antioxidant, curcumin can modulate the oxidative tone in cells due 
to its ability to inhibit lipid peroxidation and reduce ROS (Jat et al. 2013). Its 
electrophilic properties allow for covalent interaction with protein thiols and other 
nucleophilic protein residues (Awasthi et al. 2000). However, it is unlikely that 
curcumin’s antioxidant and weak electrophilic properties can account for its 
effects on more than 100 proteins. The exact nature of the chemical interaction 
between curcumin and its targets therefore remains to be determined.  
Furthermore, curcumin has shown systemic effects in a wide range of 
preclinical disease models despite what one would consider to be sub-
therapeutic plasma levels. The IC50 values reported for curcumin in vitro against 
anti-inflammatory targets COX-2 and NF-B are typically in the 10 M to 20 M 
range, which is orders of magnitude higher than the maximum reported plasma 
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levels (Gafner et al. 2004). Additionally, plasma levels of curcumin are sustained 
for short periods, with rapid clearance through the kidneys and bile reported 
(Yang et al. 2007; Lao et al. 2006). Given curcumin's virtual absence in tissues 
where efficacy has been demonstrated, it has been posited that its effects could 
be ultimately mediated by its more abundant and/or more potent metabolites 
(Heger et al. 2014b; Shen and Ji 2012). The pleiotropic effects of curcumin could 
be reconciled by implicating the involvement of multiple, chemically diverse 
metabolites, such as those formed during oxidative transformation. 
The known curcumin metabolites (e.g., reduction, conjugation and 
cleavage products) have been shown to retain bioactivity against some targets, 
but are generally less potent than curcumin (Heger et al. 2014; Pfeiffer et al. 
2006). None of these metabolites are implicated as ultimate mediators of 
curcumin’s effects (Shen and Ji 2012; Heger et al. 2014). The oxidative 
metabolites represent novel players in the discussion of potentially bioactive 
curcumin metabolites. The oxidative metabolites represent a range of different-
strength nucleophiles (2-8) and electrophiles (quinone methide and 6) and are 
likely to affect different targets. The proposed reaction of the quinone methide 
with cysteine thiols is illustrated in figure 4.1. The isolation and identification of 
these metabolites now allow us to assess their biological effects. The 
overarching hypothesis is that the oxidative metabolites are the ultimate 
mediators of some of the biological effects of curcumin. 
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Curcumin quinone methide and spiroepoxide can adduct to protein thiols 
There are several examples of phenolic compounds for which 
bioactivation to a quinone methide is implicated in its biological effects (e.g., 
eugenol and quercetin) (Thompson, Barhoumi, and Burghardt 1998; Mahmoud et 
al. 2000). Quinone methides exhibit a wide range of reactivity and biological 
effects. They mediate the therapeutic effects of anti-cancer agents and through 
covalent interactions with proteins (tamoxifen) and DNA (mitomycin C), or exert 
cytoprotective effects due to the induction of NRF2 signaling ( nitric oxide-
donating aspirin prodrugs) (Fan and Bolton 2001; Peterson and Fisher 1986; 
Dunlap et al. 2012).  
We have already shown data that suggest the curcumin quinone methide 
acts as an electrophile to mediate its effect on topoisomerase. Many other 
targets of curcumin are similarly regulated by electrophilic adduction to reactive 
quinone methides. These include the transcription factor NF-B. NF-B is an 
important target due to its prominent roles in cancer and inflammation. Reactive 
electrophiles, such as quinone methides and epoxides, inhibit NF-κB activation 
through covalent modification of Cys-179 in the activation loop of IKKβ (Pandey 
et al. 2007). Curcumin is a weak electrophile, and preliminary data in our lab 
suggest that is does not readily adduct to the IKKβ173-187  peptide. LC-MS analysis 
of the IKKβ173-187 peptide before (Figure 4.2A) and after (Figure 4.2B) reaction 
with autoxidizing curcumin shows that, in the presence of curcumin, the detected 
m/z for the peptide increase by 400 amu, equivalent to the addition of 6, or 
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curcumin quinone methide + O2. No adduct was detected with the untransformed 
curcumin or with the stable curcumin analog, methylcurcumin. We hypothesize 
that the inhibition of NF-B by curcumin depends on its oxidative activation to the 
more reactive quinone methide or spiroepoxide that ultimately adduct to IKK.  
 
O
OCH3
quinone methide
OH
OCH3
Cys-S
Michael adduct
Cys-SH
 
FIGURE 4.1 Proposed reaction of curcumin quinone methide with cysteine thiols. 
 
 
FIGURE 4.2 Reaction of curcumin oxidative metabolite with IKK173-187.  
 
  Preliminary studies also suggest that the spiroepoxide 6 can act as 
an electrophile and exhibits reactivity towards model cysteine thiol GSH. HPLC 
analysis shows the consumption of 6a and 6b upon the addition of 2 mM GSH 
A 
B
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(Figure 4.3A). The putative spiroepoxide-GSH conjugate co-eluted with the left 
over GSH at 1.9 min in (Figure 4.3B). LC-MS analysis of a reaction of isolated 6 
with GSH shows a peak at m/z 577, representing the expected mass of the 
adduct (m/z 706) with the characteristic neutral loss of glutamate (m/z 129) 
(Figure 4.3C & D). 
 
 
FIGURE 4.3: Reaction of the spiroepoxide 6  with  GSH. A and B show HPLC analysis of 
curcumin autoxidation reactions before and after the addition of 2mM GSH, respectively. 
C and D show LC-MS analysis of isolated 6a and 6b before and after the addition of 
2mM GSH, respectively. 
 
 The complex nature of the effects of reactive electrophiles is illustrated in 
the fact that GSH depletion by quinone methide is associated with both 
cytoprotective as well as cytotoxic effects (Guyton, Thompson, and Kensler 
2014). The mutagenic effects of quinone methides is associated with its 
anticancer bioactivity, but also hepatic toxicity and leukemia (Sharma et al. 
2012). Whether the formation of quinone methide and spiroepoxide in vivo will 
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result in protective or toxic effects effects seems to be based on narrow margins. 
Therefore, the formation of reactive quinone methide and epoxide intermediates 
usually elicits some concern of possible toxic effects. This concern is greatly 
lessened in the case of curcumin since no significant adverse effects have so far 
been reported despite centuries of use. 
 
Curcumin -diketones may adduct to protein sulfenic acids. 
Sullfenic acid modification in proteins has been detected due to specific 
reactivity with a model compound dimedone. Dimedone is a -diketone, a feature 
shared by the bicyclopentadione and the other products of curcumin 
autoxidation. In fact, the oxidative metabolites represents a range of nucleophilic 
-diketones as can be inferred from the extreme polarity of the compounds in 
HPLC and rapid rate of exchange in the proton attached at C4 from 1H NMR 
experiments. We hypothesize that the -diketone moiety of the oxidative 
metabolites will permit selective reactivity with protein sulfenic acid to inhibit NF-
κB, and other proteins regulated by sulfenic acids (Figure 4.4). 
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FIGURE 4.4 Proposed reaction of sulfenic acids (Cys-SOH) with dimenone (A) and 
curcumin cyclopentadione (B)  
 
In conclusion, our studies for the first time present a complete profile of the 
products of curcumin oxidative transformation and detail their mechanism of 
formation. The isolation and identification of the oxidative products, along with 
the elucidation of the reaction mechanism, will allow for future studies in further 
assessing their involvement in the biological activities of curcumin. Moreover, the 
oxidative reaction mechanism we describe, and the biological effects we propose 
for these metabolites, can serve as a model for the metabolism of mechanism of 
action for other phenolic compounds. 
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APPENDIX 
 
TABLE A1: ESI/HR/MS and LC-MS/MS analysis of curcumin oxidation products.  
Product Major Product Ions 
HR-MS (ESI) [M-H]- 
Found       Calculated Error (ppm) 
2a 249; 151 401.1249 401.1236 3.2 
2b 249; 151 401.1261 401.1236 6.2 
3 247; 151; 355; 313 399.1099 399.1080 4.8 
4 247; 151; 355; 313 399.1084 399.1080 1.0 
5 173; 217; 271 367.1195 367.1182 3.5 
6a 259; 315; 355 399.1088 399.1080 2.0 
6b 259; 313; 355 399.1086 399.1080 1.5 
7a 247; 151 399.1092 399.1080 2.3 
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Table B1-8:  1H and 13C NMR chemical shifts and couplings of curcumin oxidation 
products. The spectra were recorded on a Bruker AV-II 600 MHz spectrometer 
equipped with a cryoprobe. 13C chemical shifts were determined from HMBC and 
HSQC experiments. 
 
 
 
 
 
 
 
 
Position 1H 
(ppm) 
Multi- 
plicity 
J (Hz) 13C 
 (ppm)
COSY HMBC 
1 3.76 d 3.18 46 2 2’;6’
2 3.34 d 3.18 47 1 1’
3 - - - 206 - - 
4 4.7 s - 104 - - 
5 - - - 206 - - 
6 3.34 d 3.18 47 7 1’' 
7 3.76 d 3.18 46 6 6'’;2'' 
1’ - - - 132 - - 
2’ 6.41 d 1.8 120 6' 1;6’2’
3’ - - - 147 - - 
4’ - - - 144 - - 
5’ 6.55 d 8.1 112 6' 3’;1’
6’ 6.59 dd 8.1, 1.86 114 2 1;5’;
-OCH3' 3.62 s - 54.8 - 3' 
1” - - - 132 - - 
2” 6.41 d 1.8 120 6" 1;6"2"
3” - - - 147 - - 
4” - - - 144 - - 
5” 6.55 d 8.1 112 6'' 3";1"
6” 6.59 dd 8.1, 1.86 114 2 1;5"
-OCH3'' 3.62 s - 54.8 - 3" 
 
 
 
 
 
 
 
HO
H3CO
OH
HO O
OCH3
OHHO
2''
4''
5''
1'
4'
6'TABLE B1: 1H and 13C NMR chemical shifts 
and couplings of product  2a (600.13 MHz, 
MeOD). 
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Position 1H 
(ppm) 
Multi- 
plicity 
J (Hz) 13C 
 (ppm)
COSY HMBC  
1 4.51 d 9.0 77 2 2’;6’;1’;3
2 2.30 dd 8.9;2.9 51 1;6 7;1;1’;3
3 - - - 207 - -
4 3.84 s - x - -
5 - - - x - - 
6 2.52 dd 2.8;3.9 52 2;7 7;1”
7 4.34 d 3.4 73 6 -
1’ - - - x - - 
2’ 6.69 d 1.8 109 -OCH3' 1;6’;4'
3’ - -  - x - -
4’ - - - x - - 
5’ 6.65 d 8.1 114 - 1’;3’
6’ 6.64 dd 8.2;1.7 119 - 1;2’
-OCH3' - s - 55 2’ 3’
1” - -  - x - - 
2” 6.59 d 1.8 109 -OCH3'' 7;6”;4”
3” - -  - x - -
4” - - - x - - 
5” 6.61 d  8.1 114 - 1”;3”
6” 6.52 dd 7.9;2.1 118 - 7;2”;4”
-OCH3" - s - 55 2” 3”
 
 
X = Expected signal not seen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HO
H3CO
OH
HO O
OCH3
OHHO
TABLE B2: 1H and 13C NMR chemical shifts 
and couplings of product  2b (600.13 MHz, 
MeOD). 
 
 
100 
 
 
 
 
 
 
 
Position 1H 
(ppm) 
Multi- 
plicity
J (Hz) 13C 
 (ppm) 
COSY HMBC  
1 5.23 d 2.4 70 - 2 
2 2.57 s - 64 3 1;6 
3 - - - x - - 
4 5.07 s - 104 - - 
5 - - - x - - 
6 3.51 d 2.2 50 5;1’; 2 
7 - - - x - - 
1’ - - - 135.4 - - 
2’ 6.95 d 1.62 108 1; 6’;4’ 6’ 
3’ - - - 147 - - 
4’ - - - 145/144 - - 
5’ 6.72 d 8.1 112 1’;3’ 6’ 
6’ 6.85 dd 8.1;x 118 1,2’;4’ 2’;5’ 
-OCH3' 3.75/3.58 - s 55.4 - 3" 
1” - - 134.8 - - 
2” 6.01 d 1.6 111 4”;6” 6” 
3” - - - 146.5 - - 
4” - - - 143.6/143 - - 
5” 6.52 d 8.1 112 1”;3” 6” 
6” 6.29 dd 8.2;1.9 119 2”;4” 2”;5” 
-OCH3'' 3.75/3.58 - s 55.4 - 3" 
 
X = Expected signal not seen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE B3: 1H and 13C NMR chemical shifts 
and couplings of product 3 (600.13 MHz, 
MeOD). 
HO
H3CO
OH
HO O
OCH3
O
OH
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Position 1H  (ppm) Multi- plicity J (Hz) 
13C 
 (ppm) COSY HMBC  
1 5.26 s - 69.6 - 2 
2 3.23 s - 58 - 1,6 
3 - - - x - - 
4 x - - x - - 
5 - - - x - - 
6 4.66 s - 53 - 2 
7 x - - x - - 
1’ - - - 135.7 - - 
2’ 6.80 d 1.2 108 6';4' 6’2’ 
3’ - - - 146.5 - - 
4’ - - - 144 - - 
5’ 6.54 d 8.1 114 1';3' 3’;1’ 
6’ 6.70 dd 1.44;1.08;7.8;8.16 117.5 2';4' 1;5’; 
-OCH3' 3.86/3.57 s - 54 3' 3' 
1” - - - 134.5 - 
2” 7.31 - 1.44 111 6";4" 6"2" 
3” - - - 147 - - 
4” - - - 151 - - 
5” 6.75 - 8.28 114 1";3" 3";1" 
6” 7.39 dd 1.5;1.74;8.28,8.52 124 2";4" 1;5" 
-OCH3'' 3.86/3.57 s - 54 3" 3" 
 
 
X = Expected signal not seen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE B4: 1H and 13C NMR chemical shifts 
and couplings of product  4 (600.13 MHz, 
MeOD). OCH3
HO
OHO
OH
OO
H3CO
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Position 1H 
(ppm) 
Multi- 
plicity 
J (Hz) 13C 
 (ppm)
COSY HMBC  
1 4.55 s - 72 2 2;2’;6’;3 
2 2.64 d 2.45 51 1 1;5
3 - - - 206 - - 
4 x - - x - - 
5 - - - 206 - - 
6 2.64 d 2.45 51 7 7;2
7 4.55 s - 72 6 6;2”;6”;5 
1’ - - - 134 - - 
2’;2” 6.71 d 1.68 109 1;6 1;6'; 4' 
3’;3” - - - 146.7 - - 
4’,4” - - - 145 - - 
5’;5” 6.66 d 8.1 114 6; 1’,3’
6’,5” 6.54 dd 8.04, 1.68 118 5;1 1;2';4' 
-OCH3' 3.79 s - 54.7 - 3’
1” - - - 134 - - 
2” 6.71 d 1.68 109 1;6 1;6”; 4” 
3” - - - 146.7 - - 
4” - - - 145 - - 
5” 6.66 d 8.1 114 6; 1”,3”
6” 6.54 dd 8.04, 1.68 118 5;1 1;2”;4” 
-OCH3'' 3.79 s - 54.7 - 3”
 
 
X = Expected signal not seen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE B5: 1H and 13C NMR chemical shifts 
and couplings of product 5 (600.13 MHz, 
MeOD). 
HO
H3CO
OH
HO O
OCH3
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Position 1H 
(ppm) 
Multi- 
plicity 
J (Hz) 13C 
 (ppm)
COSY HMBC  NOESY     
1 3.28 d 9 68.2 2 6’;3 - 
2 2.63 dd 1.8, 8.9 44.5 1;6 3,1’,1 2”;6”;6 
3 - - - 203 - - - 
4 4.90 s - 103.5 - - - 
5 - - - 204 - - - 
6 2.91 dd 2.7, 2.2 57.0 1;7 5;1;2 2;2”;6” 
7 5.20 d 2.7; 71.5 6 2;6”;1”5 6;2”;6” 
1’ - - - 59.2 - - - 
2’ 5.25 d 2.34 111.5 6’ 4’;6’;1’ 2 
3’ - - - 153.5 - - - 
4’ - - - 184 - - - 
5’ 6.32 d 9.90 130.2 6’ 3’;1’ - 
6’ 6.52 dd 2.46, 9.96 150.3 5’;2’ 4’,2’ 1 
-OCH3' 3.6 s - 54 - 3’ - 
1” - - - 135.5 - - - 
2” 7.06 d 1.9 109.5 6” 7,6”,4” 6;2;7 
3” - - - 147.3 - - - 
4” - - - 144.7 - - - 
5” 6.74 d 8.16 114.0 6” 1”;3” - 
6” 6.89 dd 2.0, 8.1 118 5”;2” 2”;7;4” 6;2;7 
-OCH3'' 3.8 s - 55 - 4’ - 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE B6: 1H and 13C NMR chemical shifts 
and couplings of product 6a (MeOD). 
 
O
H3CO
OH
HO O
OCH3
OHO
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Position 1H 
(ppm) 
Multi- 
plicity 
J (Hz) 13C 
 (ppm)
COSY HMBC  
1 3.40 d 8.26 67.6 2 2;6’
2 2.37 dd 8.34,2.04 42 6,1 3;7;1;6 
3 - - - 202 - - 
4 4.76 s - 101.7 - - 
5 - - - 205 - - 
6 2.97 dd 7.71, 2.10 55 7;2 1;7;1”5 
7 4.82 d 7.60 76 6 2;2”6”;5 
1’ - - - 59.5 - 
2’ 5.28 d 2.44 111 6’ 4’;3’,6’ 
3’ - - - 153.5 - - 
4’ - - - 181 - - 
5’ 6.36 d 9.90 130 6’ 3’;1'
6’ 6.59 dd 2.48,9.90 149.8 5’;2’ 4’;2’
-OCH3' 3.6 s - 54 - 3’
1” - - - 132 - - 
2” 7.01 d 1.74 110.5 6”; 7;6”;4” 
3” - - - 147 - - 
4” - - - 146 - - 
5” 6.72 d 8.10 114 6” 1”;3”
6” 6.84 dd 8.10,1.92 119.8 5”;2” 2”;7;4” 
-OCH3'' 3.8 s  - 54 - 4’
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE B7: 1H and 13C NMR chemical shifts 
and couplings of product 6b (600.13 MHz, 
MeOD). 
O
H3CO
OH
HO O
OCH3
OHO
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Position 1H 
(ppm) 
Multi- 
plicity 
J (Hz) 13C 
 (ppm)
COSY HMBC  
1 7.15 d 1.20 142.3 6 6; 2; 3 
2 - - - 108.7 - - 
3 - - - 187.6 - - 
4 4.60 s - 103.6 - 6; 2
5 - - - 210.7 - - 
6 6.68 dd 4.04, 1.43 55.2 7; 1 5
7 5.30 d 4.08 73.1 6 2
1’ - - - 147 - - 
2’ 6.43 d 2.72 104.1 6’ 6’; 4’
3’ - - - 147.3 - - 
4’ - - - 143.5 - - 
5’ 6.70 d 8.65 113.5 6’ 3’
6’ 6.37 dd 8.62; 2.72 111.4 5’; 2’ 2’; 4’; 3’ 
-OCH3' 3.76 - - 55.3 - - 
1” - - - 131.8 - - 
2” 6.80 d 2.00 109.8 6” 1; 6”; 4” 
3” - - -    147.3 - - 
4” - - - 142.7 - - 
5” 6.74 d 8.11 114.2 6” 3”
6” 6.65 dd 8.12; 1.84 118.9 5”; 2” 1; 2”4” 
-OCH3'' 3.73 - - 55.3 - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE B8: 1H and 13C NMR chemical shifts  
and couplings of product 7a (600.13 MHz, 
CDCl3) 
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FIGURE B1: Partial 1H NMR Spectra of the bicyclopentadione 8 and Methyl-
bicyclopentadione. Protons in the R" ring of methyl-bicyclopentadione are shifted relative 
to those of 8. The spectra were acquired in acetone-d3.  
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FIGURE B4: NMR Spectra of 3 
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FIGURE B5: NMR Spectra of 4 
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FIGURE B9: NMR Spectra of 7a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.03.54.04.55.05.56.06.57.0
3.
23
3.
24
3.
24
3.
25
3.
55
3.
56
3.
68
3.
68
3.
68
3.
68
3.
73
3.
75
3.
76
3.
77
3.
78
3.
82
3.
83
3.
90
4.
60
4.
90
5.
30
5.
30
5.
32
5.
33
5.
82
5.
83
6.
36
6.
36
6.
37
6.
38
6.
43
6.
43
6.
47
6.
53
6.
60
6.
64
6.
64
6.
65
6.
66
6.
67
6.
67
6.
69
6.
70
6.
71
6.
73
6.
74
6.
80
1.
20
1.
35
0.
48
0.
89
0.
60
1.
18
0.
79
0.
76
1.
00
0.
96
2.
15
2.
14
1.
10
1.
76
1.
30
0.
84
1 H NMR OF Curcumin aux. Inter C ( rt. 6')   CD3CN  284K
ppm
2.02.53.03.54.04.55.05.56.06.57.0 ppm
50
60
70
80
90
100
110
120
ppm
-111 10 9 8 7 6 5 4 3 2 1 0 ppm
160
140
120
100
80
60
40
20
Product 7a, June 20, 2012
Product 7a, June 20, 2012 ‐ HSQC  Product 7a, Oct.  09, 2012 ‐ HMBC 
 
 
115 
 
REFERENCES 
 
Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of 
curcumin, the anti-inflammatory agent, against neurodegenerative, 
cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. 
The International Journal of Biochemistry & Cell Biology, 41(1), 40–59.  
Al-Amiery, A. A., Kadhum, A. A. H., et al. (2013). Synthesis and antioxidant 
activities of novel 5-chlorocurcumin, complemented by semiempirical 
calculations. Bioinorganic Chemistry and Applications, 2013, 354982.  
Anand, P., Thomas, S. G., et al. (2008). Biological activities of curcumin and its 
analogues (Congeners) made by man and Mother Nature. Biochemical 
Pharmacology, 76(11), 1590–1611.  
Aoki, H., Takada, Y., et al. (2007). Evidence that curcumin suppresses the 
growth of malignant gliomas in vitro and in vivo through induction of 
autophagy: role of Akt and extracellular signal-regulated kinase signaling 
pathways. Molecular Pharmacology, 72(1), 29–39.  
Awasthi, S., Pandya, U., et al. (2000). Curcumin–glutathione interactions and the 
role of human glutathione S-transferase P1-1. Chemico-Biological 
Interactions, 128(1), 19–38.  
Balasubramanian, K. (2006). Molecular Orbital Basis for Yellow Curry Spice 
Curcumin’s Prevention of Alzheimer's Disease. Journal of Agricultural and 
Food Chemistry, 54(10), 3512–3520.  
Barclay, L. R., Vinqvist, M. R., et al. (2000). On the antioxidant mechanism of 
curcumin: classical methods are needed to determine antioxidant 
mechanism and activity. Organic Letters, 2(18), 2841–3.  
Barzegar, A., & Moosavi-Movahedi, A. A. (2011). Intracellular ROS protection 
efficiency and free radical-scavenging activity of curcumin. PloS One, 6(10), 
e26012.  
Belcaro, G., Cesarone, M. R., et al. (2010). Efficacy and safety of Meriva®, a 
curcumin-phosphatidylcholine complex, during extended administration in 
osteoarthritis patients. Alternative Medicine Review, 15(4), 337–44.  
Bender, R. P., Ham, L., & Osheroff, N. (2007). Quinone-induced enhancement of 
DNA cleavage by human topoisomerase IIalpha: adduction of cysteine 
residues 392 and 405. Biochemistry, 46(10), 2856–64. 
 
 
116 
 
Bera, R., Sahoo, B. K., Ghosh, K. S., & Dasgupta, S. (2008). Studies on the 
interaction of isoxazolcurcumin with calf thymus DNA. International Journal 
of Biological Macromolecules, 42(1), 14–21.  
Chandran, B., & Goel, A. (2012). A randomized, pilot study to assess the efficacy 
and safety of curcumin in patients with active rheumatoid arthritis. 
Phytotherapy Research : PTR, 26(11), 1719–25. 
Chanpoo, M., Petchpiboonthai, H., et al. (2010). Effect of curcumin in the 
amelioration of pancreatic islets in streptozotocin-induced diabetic mice. 
Journal of the Medical Association of Thailand, S152–9.  
Chen, F., & Shi, X. (2002). Signaling from toxic metals to NF-kappaB and 
beyond: not just a matter of reactive oxygen species. Environmental Health 
Perspectives, 110 Suppl , 807–11.  
Chen, Y., Shu, W., et al. (2007). Curcumin, both histone deacetylase and 
p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B 
and Notch 1 in Raji cells. Basic & Clinical Pharmacology & Toxicology, 
101(6), 427–33. 
Chignell, C. F., Bilskj, P., et al. (1994). Spectral and photochemical properties of 
curcumin. Photochemistry and Photobiology, 59(3), 295–302. 
Chuengsamarn, S., Rattanamongkolgul, S., et al. (2014). Reduction of 
atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a 
randomized controlled trial. The Journal of Nutritional Biochemistry, 25(2), 
144–50.  
Cooper, C. E., Patel, R. P., et al. (2002). Nanotransducers in cellular redox 
signaling: modification of thiols by reactive oxygen and nitrogen species. 
Trends in Biochemical Sciences, 27(10), 489–492.  
Denk, A., Goebeler, M., et al. (2001). Activation of NF-kappa B via the Ikappa B 
kinase complex is both essential and sufficient for proinflammatory gene 
expression in primary endothelial cells. The Journal of Biological Chemistry, 
276(30), 28451–8. 
Dennehy, M. K., Richards, K. A. M., et al. (2006). Cytosolic and nuclear protein 
targets of thiol-reactive electrophiles. Chemical Research in Toxicology, 
19(1), 20–9.  
Deweese, J. E., & Osheroff, N. (2009). The DNA cleavage reaction of 
topoisomerase II: wolf in sheep’s clothing. Nucleic Acids Research, 37(3), 
738–48.  
 
 
117 
 
Dunlap, T., Piyankarage, S. C., et al. (2012). Quinone-induced activation of 
Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide. 
Chemical Research in Toxicology, 25(12), 2725–36.  
Fan, P. W., & Bolton, J. L. (2001). Bioactivation of tamoxifen to metabolite E 
quinone methide: reaction with glutathione and DNA. Drug Metabolism and 
Disposition, 29(6), 891–6.  
Gafner, S., Lee, S., et al. (2004). Biologic evaluation of curcumin and structural 
derivatives in cancer chemoprevention model systems. Phytochemistry, 
65(21), 2849–59.  
Goel, A., Kunnumakkara, A. B., & Aggarwal, B. B. (2008). Curcumin as 
“Curecumin”: From kitchen to clinic. Biochemical Pharmacology, 75(4), 787–
809.  
Gordon, O. N., & Schneider, C. (2012). Vanillin and ferulic acid: not the major 
degradation products of curcumin. Trends in Molecular Medicine, 18(7), 
361–363.  
Griesser, M., Pistis, V., et al. (2011). Autoxidative and Cyclooxygenase-2 
Catalyzed Transformation of the Dietary Chemopreventive Agent Curcumin. 
Journal of Biological Chemistry, 286(2), 1114–1124.  
Grynkiewicz, G., & Ślifirski, P. (2012). Curcumin and curcuminoids in quest for 
medicinal status. Acta Biochimica Polonica, 59(2), 201–12.  
Guyton, K. Z., Thompson, J. A., & Kensler, T. W. (1993). Role of quinone 
methide in the in vitro toxicity of the skin tumor promoter butylated 
hydroxytoluene hydroperoxide. Chemical Research in Toxicology, 6(5), 731–
8.  
Hanai, H., Iida, T., et al. (2006). Curcumin maintenance therapy for ulcerative 
colitis: randomized, multicenter, double-blind, placebo-controlled trial. 
Clinical Gastroenterology and Hepatology, 4(12), 1502–6.  
He, Z., Shi, C., et al. (2011). Upregulation of p53 expression in patients with 
colorectal cancer by administration of curcumin. Cancer Investigation, 29(3), 
208–13.  
Heger, M., van Golen, R. F., et al. (2014). The molecular basis for the 
pharmacokinetics and pharmacodynamics of curcumin and its metabolites in 
relation to cancer. Pharmacological Reviews, 66(1), 222–307.  
 
 
118 
 
Hishikawa, N., Takahashi, Y., et al. (2012). Effects of turmeric on Alzheimer’s 
disease with behavioral and psychological symptoms of dementia. Ayu, 
33(4), 499–504. 
Hoehle, S. I., Pfeiffer, E., Sólyom, A. M., & Metzler, M. (2006). Metabolism of 
curcuminoids in tissue slices and subcellular fractions from rat liver. Journal 
of Agricultural and Food Chemistry, 54(3), 756–64.  
Holder, G. M., Plummer, J. L., & Ryan, A. J. (1978). The Metabolism and 
Excretion of Curcumin (1,7-Bis-(4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione) in the Rat. Xenobiotica, 8(12), 761–768.  
Hong, D., Zeng, X., et al. (2010). Altered profiles of gene expression in curcumin-
treated rats with experimentally induced myocardial infarction. 
Pharmacological Research, 61(2), 142–8.  
Huang, M. T., Lou, Y. R., et al.  (1998). Effect of dietary curcumin and 
dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced 
mammary tumors and lymphomas/leukemias in Sencar mice. 
Carcinogenesis, 19(9), 1697–700.  
Huang, M. T., Newmark, H. L., & Frenkel, K. (1997). Inhibitory effects of 
curcumin on tumorigenesis in mice. Journal of Cellular Biochemistry. 
Supplement, 27, 26–34.  
Ireson, C., Orr, S., et al. (2001). Characterization of Metabolites of the 
Chemopreventive Agent Curcumin in Human and Rat Hepatocytes and in 
the Rat in Vivo, and Evaluation of Their Ability to Inhibit Phorbol Ester-
induced Prostaglandin E2 Production. Cancer Res., 61(3), 1058–1064.  
Jacob, A., Wu, R., Zhou, M., & Wang, P. (2007). Mechanism of the Anti-
inflammatory Effect of Curcumin: PPAR-gamma Activation. PPAR Research, 
2007, 89369.  
Jat, D., Parihar, P., et al.. (2013). Curcumin reduces oxidative damage by 
increasing reduced glutathione and preventing membrane permeability 
transition in isolated brain mitochondria. Cellular and Molecular Biology, 59 
Suppl, OL1899–905.  
Jeong, J., Jung, Y., et al. (2011). Novel oxidative modifications in redox-active 
cysteine residues. Molecular & Cellular Proteomics, 10(3), M110.000513.  
Johnson, J. J., & Mukhtar, H. (2007). Curcumin for chemoprevention of colon 
cancer. Cancer Letters, 255(2), 170–181.  
 
 
119 
 
Jovanovic, S. V., Boone, C. W., et al. (2001). How Curcumin Works Preferentially 
with Water Soluble Antioxidants. Journal of the American Chemical Society, 
123(13), 3064–3068. 
Jurrmann, N., Brigelius-Flohe, R., & Bol, G. (2005). Curcumin Blocks Interleukin-
1 (IL-1) Signaling by Inhibiting the Recruitment of the IL-1 Receptor-
Associated Kinase IRAK in Murine Thymoma EL-4 Cells. J. Nutr., 135(8), 
1859–1864.  
Ketron, A. C., Gordon, O. N., et al. (2013). Oxidative metabolites of curcumin 
poison human type II topoisomerases. Biochemistry, 52(1), 221–7.  
Ketterer, B. (1988). Protective role of glutathione and glutathione transferases in 
mutagenesis and carcinogenesis. Mutation Research, 202(2), 343–361. 
Khurana, A., & Ho, C. (1988). High Performance Liquid Chromatographic 
Analysis of Curcuminoids and Their Photo-oxidative Decomposition 
Compounds in Curcuma Longa L. Journal of Liquid Chromatography, 
11(11), 2295–2304.  
Kim, H., Jeong, E. S., et al. (2013). Glucuronidation of a sarpogrelate active 
metabolite is mediated by UDP-glucuronosyltransferases 1A4, 1A9, and 
2B4. Drug Metabolism and Disposition, 41(8), 1529–37.  
Koonammackal, M. V., Nellipparambil, U. V. N., & Sudarsanakumar, C. (2011). 
Molecular dynamics simulations and binding free energy analysis of DNA 
minor groove complexes of curcumin. Journal of Molecular Modeling, 17(11), 
2805–16.  
Lao, C. D., Ruffin, M. T., et al. (2006). Dose escalation of a curcuminoid 
formulation. BMC Complementary and Alternative Medicine, 6, 10. 
Lee, B. H., Choi, H. A., et al.  (2013). Changes in chemical stability and 
bioactivities of curcumin by ultraviolet radiation. Food Science and 
Biotechnology, 22(1), 279–282.  
Leong-Skornicková, J., Sída, O., et al. (2007). Chromosome numbers and 
genome size variation in Indian species of Curcuma (Zingiberaceae). Annals 
of Botany, 100(3), 505–26.  
Leung, M. H. M., & Kee, T. W. (2009). Effective stabilization of curcumin by 
association to plasma proteins: human serum albumin and fibrinogen. 
Langmuir, 25(10), 5773–7. 
 
 
120 
 
Li, Z., Ouyang, K., et al. (2009). Curcumin induces apoptosis and inhibits growth 
of human Burkitt’s lymphoma in xenograft mouse model. Molecules and 
Cells, 27(3), 283–9.  
Litwinienko, G., & Ingold, K. U. (2004). Abnormal solvent effects on hydrogen 
atom abstraction. 2. Resolution of the curcumin antioxidant controversy. The 
role of sequential proton loss electron transfer. The Journal of Organic 
Chemistry, 69(18), 5888–96.  
Liu, Y., Yang, Z., et al. (2008). Interaction of curcumin with intravenous 
immunoglobulin: a fluorescence quenching and Fourier transformation 
infrared spectroscopy study. Immunobiology, 213(8), 651–61.  
Lopachin, R. M., & Decaprio, A. P. (2005). Protein adduct formation as a 
molecular mechanism in neurotoxicity. Toxicological Sciences, 86(2), 214–
25.  
López-Lázaro, M., Willmore, E., et al. (2007). Curcumin Induces High Levels of 
Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells. Journal 
of Natural Products, 70(12), 1884–1888.  
Mahajan, M. K., Uttamsingh, V., et al. (2011). In vitro metabolism of 
oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug 
Metabolism and Disposition, 39(4), 693–702.  
Mahmoud, N. N., Carothers, A. M., et al. (2000). Plant phenolics decrease 
intestinal tumors in an animal model of familial adenomatous polyposis. 
Carcinogenesis, 21(5), 921–7.  
Marczylo, T. H., Verschoyle, R. D., et al. (2007). Comparison of systemic 
availability of curcumin with that of curcumin formulated with 
phosphatidylcholine. Cancer Chemotherapy and Pharmacology, 60(2), 171–
7. 
Mashayekhi, S. O., Sattari, M. R., & Routledge, P. A. (2010). Evidence of active 
transport involvement in morphine transport via MDCKII and MDCK-PGP 
cell lines. Research in Pharmaceutical Sciences, 5(2), 99–106.  
Masuda, T., Hidaka, K., et al. (1999). Chemical Studies on Antioxidant 
Mechanism of Curcuminoid:  Analysis of Radical Reaction Products from 
Curcumin. Journal of Agricultural and Food Chemistry, 47(1), 71–77.  
Metzler, M., Pfeiffer, E., Schulz, S. I., & Dempe, J. S. (2013). Curcumin uptake 
and metabolism. BioFactors, 39(1), 14–20.  
 
 
121 
 
Nafisi, S., Adelzadeh, M., Norouzi, Z., & Sarbolouki, M. N. (2009). Curcumin 
binding to DNA and RNA. DNA and Cell Biology, 28(4), 201–8.  
Nitiss, J. L. (1998). Investigating the biological functions of DNA topoisomerases 
in eukaryotic cells. Biochimica et Biophysica Acta, 1400(1-3), 63–81.  
O’Brien, P. J. (1988). Radical formation during the peroxidase catalyzed 
metabolism of carcinogens and xenobiotics: the reactivity of these radicals 
with GSH, DNA, and unsaturated lipid. Free Radical Biology & Medicine, 
4(3), 169–83.  
Ogilvie, B. W., Zhang, D., et al. (2006). Glucuronidation converts gemfibrozil to a 
potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-
drug interactions. Drug Metabolism and Disposition, 34(1), 191–7.  
Olszanecki, R., Jawień, J., et al. (2005). Effect of curcumin on atherosclerosis in 
apoE/LDLR-double knockout mice. Journal of Physiology and 
Pharmacology, 56(4), 627–35.  
Ono, K., Hasegawa, K., et al. (2004). Curcumin has potent anti-amyloidogenic 
effects for Alzheimer’s beta-amyloid fibrils in vitro. Journal of Neuroscience 
Research, 75(6), 742–50.  
Pabon, H. J. J. (1964). A synthesis of curcumin and related compounds. Recueil 
Des Travaux Chimiques Des Pays-Bas, 83(4), 379–386.  
Pan, M., Huang, T., & Lin, J. (1999). Biotransformation of Curcumin Through 
Reduction and Glucuronidation in Mice. Drug Metab. Dispos., 27(4), 486–
494.  
Pandey, M. K., Sandur, S. K., et al. (2007). Butein, a tetrahydroxychalcone, 
inhibits nuclear factor (NF)-B and NF-B-regulated gene expression 
through direct inhibition of IKK on cysteine 179 residue. The Journal of 
Biological Chemistry, 282(24),  
Pandya, A., Goswami, H., et al. (2012). A novel nanoaggregation detection 
technique of TNT using selective and ultrasensitive nanocurcumin as a 
probe. The Analyst, 137(8), 1771–4.  
Pasternak, G. W., Bodnar, R. J., et al. (1987). Morphine-6-glucuronide, a potent 
mu agonist. Life Sciences, 41(26), 2845–9.  
Pawar, Y. B., Munjal, B., et al. (2012). Bioavailability of a lipidic formulation of 
curcumin in healthy human volunteers. Pharmaceutics, 4(4), 517–30.  
 
 
122 
 
Perry, M., Demeule, M., et al. (2010). Curcumin inhibits tumor growth and 
angiogenesis in glioblastoma xenografts. Molecular Nutrition & Food 
Research, 54(8), 1192–201.  
Peterson, D. M., & Fisher, J. (1986). Autocatalytic quinone methide formation 
from mitomycin c. Biochemistry, 25(14), 4077–84.  
Pfeiffer, E., Hoehle, S. I., et al. (2006). Curcuminoids Form Reactive 
Glucuronides In Vitro. Journal of Agricultural and Food Chemistry, 55(2), 
538–544.  
Poole, L. B., Zeng, B., et al. Synthesis of chemical probes to map sulfenic acid 
modifications on proteins. Bioconjugate Chemistry, 16(6), 1624–8. doi: 
Priyadarsini, K. I., Maity, D. K., et al. (2003). Role of phenolic O-H and methylene 
hydrogen on the free radical reactions and antioxidant activity of curcumin. 
Free Radical Biology & Medicine, 35(5), 475–84.  
Quitschke, W. W., Steinhauff, N., & Rooney, J. (2013). The effect of cyclodextrin-
solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: 
brain uptake and metabolism after intravenous and subcutaneous injection. 
Alzheimer’s Research & Therapy, 5(2), 16.  
Ranjan, A. P., Mukerjee, A., et al. (2013). Efficacy of Liposomal Curcumin in a 
Human Pancreatic Tumor Xenograft Model: Inhibition of Tumor Growth and 
Angiogenesis. Anticancer Res, 33(9), 3603–3609.  
Ravindran, J., Prasad, S., & Aggarwal, B. B. (2009). Curcumin and cancer cells: 
how many ways can curry kill tumor cells selectively? AAPS J, 11(3), 495–
510. 
Ravindranath, V., & Chandrasekhara, N. (1980). Absorption and tissue 
distribution of curcumin in rats. Toxicology, 16(3), 259–265.  
Ravindranath, V., & Chandrasekhara, N. (1981). Metabolism of curcumn-studies 
with [3H]curcumin. Toxicology, 22(4), 337–344.  
Reddie, K. G., & Carroll, K. S. (2008). Expanding the functional diversity of 
proteins through cysteine oxidation. Current Opinion in Chemical Biology, 
12(6), 746–54.  
Ritter, J. K. (2000). Roles of glucuronidation and UDP-glucuronosyltransferases 
in xenobiotic bioactivation reactions. Chemico-Biological Interactions, 129(1-
2), 171–193. 
 
 
123 
 
Sanphui, P., Goud, N. R., et al. (2011). New polymorphs of curcumin. Chemical 
Communications, 47(17),  
Sasikumar, B. (2005). Genetic resources of Curcuma: diversity, characterization 
and utilization. Plant Genetic Resources, 3(2), 230–251.  
Selvam, C., Jachak, S. M., Thilagavathi, R., & Chakraborti, A. K. (2005). Design, 
synthesis, biological evaluation and molecular docking of curcumin 
analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory 
agents. Bioorganic & Medicinal Chemistry Letters, 15(7), 1793–7.  
Sharma, A. M., Li, Y., et al. (2012). Bioactivation of nevirapine to a reactive 
quinone methide: implications for liver injury. Chemical Research in 
Toxicology, 25(8), 1708–19. 
Shen, L., & Ji, H.-F. (2009). Contribution of degradation products to the 
anticancer activity of curcumin. Clinical Cancer Research, 15(22), 7108;  
Shen, L., & Ji, H. (2012). The pharmacology of curcumin: is it the degradation 
products? Trends in Molecular Medicine, 18(3), 138–44.  
Singh, M., Ramos, I., Asafu-Adjei, D., et al. (2013). Curcumin improves the 
therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with 
improved T-cell responses in blood of a triple-negative breast cancer model 
4T1. Cancer Medicine, 2(4), 571–82.  
Singh, S., & Khar, A. (2006). Biological effects of curcumin and its role in cancer 
chemoprevention and therapy. Anticancer Agents in Medicinal Chemistry, 
6(3), 259–270.  
Sinha, R., Anderson, D. E., McDonald, S. S., & Greenwald, P. (2003). Cancer 
risk and diet in India. Journal of Postgraduate Medicine, 49(3), 222–8.  
Sperker, B., Backman, J. T., & Kroemer, H. K. (1997). The role of beta-
glucuronidase in drug disposition and drug targeting in humans. Clinical 
Pharmacokinetics, 33(1), 18–31.  
Sperker, B., Werner, U., et al. (2000). Expression and function of β-
glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn-
Schmiedeberg’s Archives of Pharmacology, 362(2), 110–115. 
Stiborová, M., Poljaková, J., et al. (2007). Mammalian peroxidases activate 
anticancer drug ellipticine to intermediates forming deoxyguanosine adducts 
in DNA identical to those found in vivo and generated from 12-
hydroxyellipticine and 13-hydroxyellipticine. International Journal of Cancer, 
120(2), 243–51.  
 
 
124 
 
Strimpakos, A. S., & Sharma, R. A. (2008). Curcumin: preventive and therapeutic 
properties in laboratory studies and clinical trials. Antioxidants & Redox 
Signaling, 4(14), 2909–2911. 
Su, C., Yang, J., Lu, C., et al. (2010). Curcumin inhibits human lung large cell 
carcinoma cancer tumour growth in a murine xenograft model. Phytotherapy 
Research, 24(2), 189–92.  
Sun, Y., Wang, R., Yuan, S., Lin, X., & Liu, C. (2010). Theoretical study on the 
antioxidant activity of curcumin. Chinese Journal of Chemistry, 22(8), 827– 
Sun, Y., Zhang, H., Chen, D., & Liu, C. (2002). Theoretical Elucidation on the 
Antioxidant Mechanism of Curcumin:  A DFT Study. Organic Letters, 4(17), 
2909–2911. 
Suzuki, M., Betsuyaku, T., et al. (2009). Curcumin attenuates elastase- and 
cigarette smoke-induced pulmonary emphysema in mice. American Journal 
of Physiology. Lung Cellular and Molecular Physiology, 296(4), L614–23.  
Szewczuk, L. M., Lee, S. H., et al. (2005). Viniferin formation by COX-1: 
evidence for radical intermediates during co-oxidation of resveratrol. Journal 
of Natural Products, 68(1), 36–42.  
Thompson, D. C., Barhoumi, R., & Burghardt, R. C. (1998). Comparative toxicity 
of eugenol and its quinone methide metabolite in cultured liver cells using 
kinetic fluorescence bioassays. Toxicology and Applied Pharmacology, 
149(1), 55–63.  
Tonnesen, H. H., & Karlsen, J. (1985). Studies on curcumin and curcuminoids. 
Zeitschrift Fur Lebensmittel-Untersuchung Und -Forschung, 180(2), 132–
134.  
Vaidya, V., Ingold, K. U., & Pratt, D. A. (2009). Garlic: Source of the Ultimate 
Antioxidants-Sulfenic Acids. Angewandte Chemie, 121(1), 163–166.  
Valacchi, G., Pagnin, E. et al (2004). Inhibition of NFkappaB activation and IL-8 
expression in human bronchial epithelial cells by acrolein. Antioxidants & 
Redox Signaling, 7(1-2), 25–31.  
Vareed, S. K., Kakarala, M., et al. (2008). Pharmacokinetics of curcumin 
conjugate metabolites in healthy human subjects. Cancer Epidemiology, 
Biomarkers & Prevention, 17(6), 1411–7.  
Wahlström, B., & Blennow, G. (1978). A study on the fate of curcumin in the rat. 
Acta Pharmacologica et Toxicologica, 43(2), 86–92.  
 
 
125 
 
Wang, H., Mao, Y. et al. (2001). Stimulation of Topoisomerase II-Mediated DNA 
Damage via a Mechanism Involving Protein Thiolation. Biochemistry, 40(11), 
3316–3323.  
Wang, J. C. (1996). DNA topoisomerases. Annual Review of Biochemistry, 65, 
635–92.  
Wang, L., Li, C., Guo, H. et al. (2011). Curcumin inhibits neuronal and vascular 
degeneration in retina after ischemia and reperfusion injury. PloS One, 6(8), 
e23194.  
Wang, Y., Pan, M., Cheng, A. et al. (1997). Stability of curcumin in buffer 
solutions and characterization of its degradation products. Journal of 
Pharmaceutical and Biomedical Analysis, 15(12), 1867–1876.  
Weber, W. M., Hunsaker, L. A. et al. (2006). Activation of NFkB is inhibited by 
curcumin and related enones. Bioorganic Medicinal Chemistry, 14(7), 2450–
2461. 
Weisberg, S. P., Leibel, R., & Tortoriello, D. V. (2008). Dietary curcumin 
significantly improves obesity-associated inflammation and diabetes in 
mouse models of diabesity. Endocrinology, 149(7), 3549–58.  
Wetzelberger, K., Baba, S. P., et al.  (2010). Postischemic deactivation of cardiac 
aldose reductase: role of glutathione S-transferase P and glutaredoxin in 
regeneration of reduced thiols from sulfenic acids. The Journal of Biological 
Chemistry, 285(34), 26135–48.  
Weyel, D., Sedlacek, H. H., et al. (2000). Secreted human beta-glucuronidase: a 
novel tool for gene-directed enzyme prodrug therapy. Gene Therapy, 7(3), 
224–31.  
Wilken, R., Veena, M. S., Wang, M. B., & Srivatsan, E. S. (2011). Curcumin: A 
review of anti-cancer properties and therapeutic activity in head and neck 
squamous cell carcinoma. Molecular Cancer, 10, 12.  
Yang, K., Lin, L., Tseng, T., Wang, S., & Tsai, T. (2007). Oral bioavailability of 
curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. 
Journal of Chromatography. B, Analytical Technologies in the Biomedical 
and Life Sciences, 853(1-2), 183–9.  
Zebib, B., Mouloungui, Z., & Noirot, V. (2010). Stabilization of curcumin by 
complexation with divalent cations in glycerol/water system. Bioinorganic 
Chemistry and Applications, 292760.  
 
 
126 
 
Zhao, X., C. Wang, et al. (2013). "Chronic curcumin treatment normalizes 
depression-like behaviors in mice with mononeuropathy: involvement of 
supraspinal serotonergic system and GABAA receptor." 
Psychopharmacology: 1-17. 
 
